1 | (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 271 271 💬 |
2 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | 1件: 97 97 💬 |
3 | (-)-trans-delta-9-Tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
4 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
5 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
6 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
7 | (2)-epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 1件: 8 8 💬 |
8 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
9 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | 1件: 309 309 💬 |
10 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | 1件: 309 309 💬 |
11 | (3beta, 5beta, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 💬 |
12 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
13 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
14 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
15 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
16 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
17 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
18 | (3ß, 5ß, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 💬 |
19 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 💬 |
20 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | 1件: 79 79 💬 |
21 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
22 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
23 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
24 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | 1件: 161 161 💬 |
25 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 💬 |
26 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 💬 |
27 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
28 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
29 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
30 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
31 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | - | - | - | 1件: 97 97 💬 |
32 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
33 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
34 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 💬 |
35 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
36 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
37 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 💬 |
38 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | 1件: 6 6 💬 |
39 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | 1件: 97 97 💬 |
40 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 💬 |
41 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
42 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
43 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
44 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 💬 |
45 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
46 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 💬 |
47 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
48 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
49 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 💬 |
50 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
51 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
52 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
53 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
54 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
55 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
56 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 💬 |
57 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 💬 |
58 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 💬 |
59 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 💬 |
60 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 💬 |
61 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
62 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
63 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
64 | 0.3 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: Tropicamide
Tropicamide
💬 | 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
65 | 0.4 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
66 | 0.4mL prefilled syringes | - | - | - | - | 1件: 107 107 💬 |
67 | 0.6 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
68 | 0.6mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
69 | 0.9% Isotonic Saline (IS) | - | - | - | - | 1件: 299 299 💬 |
70 | 0.9% Isotonic Saline (IS), 4mL | - | - | - | - | 1件: 299 299 💬 |
71 | 0.9% normal saline (control) | - | - | - | - | 1件: 299 299 💬 |
72 | 0.9% physiological saline | - | - | - | - | 1件: 266 266 💬 |
73 | 0.9% saline | - | - | - | - | 2件: 6 6, 70 💬 |
74 | 0.9% sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 6 6, 14, 51, 53 💬 |
75 | 0.9% sodium chloride (normal saline) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 6 6 💬 |
76 | 0.9% Sodium Chloride Injection | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 168 168 💬 |
77 | 0.9% w/v isotonic sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 50 50 💬 |
78 | 0.9% w/v sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
79 | 009-0 | - | - | - | - | 1件: 6 6 💬 |
80 | 009-3 | - | - | - | - | 1件: 6 6 💬 |
81 | 009-4 | - | - | - | - | 1件: 6 6 💬 |
82 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 💬 |
83 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 💬 |
84 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 💬 |
85 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 💬 |
86 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
87 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
88 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
89 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 79 79 💬 |
90 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
91 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 58 58 💬 |
92 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
93 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | 2件: Butyric Acid Butyric Acid, Indole | - | - | - | 1件: 51 51 💬 |
94 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
95 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 💬 |
96 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
97 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
98 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 💬 |
99 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 💬 |
100 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
101 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
102 | 1.2 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 💬 |
103 | 1.8 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 💬 |
104 | 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
105 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | 1件: 86 86 💬 |
106 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
107 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
108 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
109 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
110 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
111 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
112 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
113 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 💬 |
114 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
115 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
116 | 118-42-3 | - | - | - | - | 1件: 46 46 💬 |
117 | 11C-BMS-986196 | - | - | - | - | 1件: 13 13 💬 |
118 | 1393641-34-3 | - | - | - | - | 1件: 13 13 💬 |
119 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 💬 |
120 | 15 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
121 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
122 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
123 | 15 or 45 mg | - | - | - | - | 1件: 67 67 💬 |
124 | 15-0 H20 | - | - | - | - | 2件: 6 6, 19 💬 |
125 | 1639325-43-1 | - | - | - | - | 1件: 254 254 💬 |
126 | 1643368-58-4 | - | - | - | - | 2件: 53 53, 160 💬 |
127 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 💬 |
128 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
129 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
130 | 18F-AV-45 | - | - | - | - | 2件: 6 6, 127 💬 |
131 | 18F] LBT-999 | - | - | - | - | 1件: 6 6 💬 |
132 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 💬 |
133 | 1[(6- Allyl- 8beta- erg | - | - | - | - | 1件: 6 6 💬 |
134 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
135 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
136 | 1[(6- Allyl- 8ß- erg | - | - | - | - | 1件: 6 6 💬 |
137 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
138 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
139 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
140 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | 2件: 19 19, 65 💬 |
141 | 2,3-dihydroxybutanedioic acid | - | - | - | - | 1件: 299 299 💬 |
142 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 💬 |
143 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: Benzoic acid
Benzoic acid
💬 | - | - | 1件: 51 51 💬 |
144 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | 1件: Famciclovir Famciclovir | 1件: Famciclovir
Famciclovir
💬 | - | - | 1件: 13 13 💬 |
145 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | 1件: 28 28 💬 |
146 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | 1件: 28 28 💬 |
147 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
148 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 💬 |
149 | 2-amino-4-(methyl[11C]sulfanyl)butanoic acid | 1件: Butyric Acid Butyric Acid | - | - | - | 1件: 34 34 💬 |
150 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 💬 |
151 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
152 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
153 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
154 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
155 | 200 mg BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
156 | 2019171-69-6 | - | - | - | - | 1件: 61 61 💬 |
157 | 207-3120 | - | - | - | - | 1件: 6 6 💬 |
158 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 💬 |
159 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
160 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
161 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 💬 |
162 | 2S,4R-(-)-ketoconazole | 1件: Ketoconazole Ketoconazole | 1件: Ketoconazole
Ketoconazole
💬 | 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
163 | 2S,4R-(-)-ketoconazole, levoketoconazole | 2件: Ketoconazole Ketoconazole, Levoketoconazole | 2件: Ketoconazole
Ketoconazole
,
Levoketoconazole
💬 | 3件: CYP11A1 CYP11A1, CYP11B1, CYP17A1 💬 | 7件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
164 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
165 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
166 | 3,4-DIAMINOPYRIDINE | - | - | - | - | 2件: 12 12, 13 💬 |
167 | 3,4-Diaminopyridine Phosphate | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 3 3 💬 |
168 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | 1件: 6 6 💬 |
169 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
170 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 💬 |
171 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
172 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
173 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 💬 |
174 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | 1件: Tromethamine Tromethamine | 1件: Tromethamine
Tromethamine
💬 | - | - | 2件: 96 96, 97 💬 |
175 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 💬 |
176 | 30 or 60 mg | - | - | - | - | 1件: 67 67 💬 |
177 | 30 or 90 mg | - | - | - | - | 1件: 67 67 💬 |
178 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
179 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
180 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
181 | 4 cholesten-3-one, oxime | - | - | - | - | 1件: 2 2 💬 |
182 | 4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulphonamide | - | - | - | - | 1件: 46 46 💬 |
183 | 4'-iodo-4'-deoxydoxorubicin | 1件: Iodine Iodine | 1件: Iodine
Iodine
💬 | - | - | 1件: 28 28 💬 |
184 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 💬 |
185 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
186 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
187 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 💬 |
188 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
189 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
190 | 4-cholesten-3-one, oxime | - | - | - | - | 2件: 2 2, 3 💬 |
191 | 4-cholesten-3-one,oxime | - | - | - | - | 1件: 3 3 💬 |
192 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
193 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
194 | 4D-310 | - | - | - | - | 1件: 19 19 💬 |
195 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 3件: Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 💬 |
196 | 5,6,7,8-tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
197 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
198 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
199 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
200 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 💬 |
201 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 💬 |
202 | 50 mg BIA 9 1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
203 | 50 mg ELX/25 mg TEZ/37.5 mg IVA | - | - | - | - | 1件: 299 299 💬 |
204 | 50 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
205 | 500 0500 0 | - | - | - | - | 1件: 19 19 💬 |
206 | 52069.00.01 | - | - | - | - | 1件: 13 13 💬 |
207 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 💬 |
208 | 552-02 | - | - | - | - | 2件: 53 53, 299 💬 |
209 | 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747 | - | - | - | - | 1件: 93 93 💬 |
210 | 6% Hypertonic Saline (HS), 4mL | - | - | - | - | 1件: 299 299 💬 |
211 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 💬 |
212 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 💬 |
213 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 💬 |
214 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 💬 |
215 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | 1件: 2 2 💬 |
216 | 6036937.00.01 | - | - | - | - | 1件: 6 6 💬 |
217 | 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
218 | 6a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
219 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
220 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
221 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
222 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
223 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
224 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
225 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
226 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
227 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
228 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
229 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
230 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
231 | 70930.00.00 | - | - | - | - | 1件: 46 46 💬 |
232 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
233 | 80 mg DR-6MP | - | - | - | - | 1件: 96 96 💬 |
234 | 800 mg ibuprofen/26.6 mg famotidine | 2件: Famotidine Famotidine, Ibuprofen | 2件: Ibuprofen
Ibuprofen
,
Famotidine
💬 | 3件: HRH2 HRH2, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 107 107 💬 |
235 | 80mg ELX / 40mg TEZ / 60mg IVA | - | - | - | - | 1件: 299 299 💬 |
236 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | 1件: 46 46 💬 |
237 | 98-92-0 | - | - | - | - | 1件: 107 107 💬 |
238 | 99mTc-3PRGD2 | - | - | - | - | 1件: 46 46 💬 |
239 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 💬 |
240 | ?-3 polyunsaturated fatty acid | - | - | - | - | 1件: 96 96 💬 |
241 | [123I]MNI-420 | - | - | - | - | 2件: 6 6, 8 💬 |
242 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
243 | [14C]-BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
244 | [18F] LBT-999 PET | - | - | - | - | 1件: 6 6 💬 |
245 | [18F]MK-9470 | - | - | - | - | 1件: 6 6 💬 |
246 | [18F]MNI-952 | - | - | - | - | 1件: 5 5 💬 |
247 | [18F]MNI-958 | - | - | - | - | 1件: 5 5 💬 |
248 | [18F]P17-059 | - | - | - | - | 1件: 6 6 💬 |
249 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 💬 |
250 | [68Ga]CBP8 | - | - | - | - | 1件: 85 85 💬 |
251 | [68Ga]Ga-PentixaFor PET/CT | - | - | - | - | 1件: 84 84 💬 |
252 | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine | 3件: Clarithromycin Clarithromycin, Clofazimine, Rifabutin | 3件: Clarithromycin
Clarithromycin
,
Clofazimine
,
Rifabutin
💬 | - | - | 1件: 96 96 💬 |
253 | A-623 | - | - | - | - | 1件: 49 49 💬 |
254 | A-623 or AMG 623 | - | - | - | - | 1件: 66 66 💬 |
255 | A-glucosidasi acida umana ricombinante coniugata con multiple copie di bis-mannosio-6- fosfato-tetra-mannosio glicano sintetico (NEOGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
256 | A4250 (400 µg) | - | - | - | - | 1件: 338 338 💬 |
257 | A4250 (600 µg) | - | - | - | - | 1件: 338 338 💬 |
258 | A4250-015 | - | - | - | - | 1件: 297 297 💬 |
259 | AAV BBP-631 | - | - | - | - | 1件: 81 81 💬 |
260 | AAV2CUhCLN2 (3x10^12 particle units) | - | - | - | - | 1件: 19 19 💬 |
261 | AAV5-RPGR 4e11 | - | - | - | - | 1件: 90 90 💬 |
262 | AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
263 | Abacavir 300mg twice daily | 1件: Abacavir Abacavir | 1件: Abacavir
Abacavir
💬 | - | - | 1件: 265 265 💬 |
264 | ABBV-006 | - | - | - | - | 1件: 97 97 💬 |
265 | ABBV-066 | - | - | - | - | 2件: 96 96, 97 💬 |
266 | ABBV-0805 | - | - | - | - | 1件: 6 6 💬 |
267 | ABBV-105, A-1519938.0 | - | - | - | - | 1件: 46 46 💬 |
268 | ABBV-3067 | - | - | - | - | 1件: 299 299 💬 |
269 | ABBV-323 | - | - | - | - | 2件: 53 53, 97 💬 |
270 | ABBV-323 Dose A | - | - | - | - | 1件: 97 97 💬 |
271 | ABBV-323 Dose B | - | - | - | - | 1件: 97 97 💬 |
272 | ABBV-3373 | - | - | - | - | 1件: 46 46 💬 |
273 | ABBV-668 | - | - | - | - | 1件: 97 97 💬 |
274 | ABBV-951 | - | - | - | - | 1件: 6 6 💬 |
275 | ABC/DTG/3TC STR - Tablet | - | - | - | - | 1件: 256 256 💬 |
276 | Abetimus sodium (LJP 394) | 1件: Abetimus Abetimus | - | - | - | 1件: 49 49 💬 |
277 | ABP 959 | - | - | - | - | 1件: 62 62 💬 |
278 | ABP 959 - biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
279 | ABP 959 - proposed biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
280 | ABT 494 | - | - | - | - | 1件: 46 46 💬 |
281 | ABT 494 12mg | - | - | - | - | 2件: 46 46, 96 💬 |
282 | ABT 494 3mg | - | - | - | - | 2件: 46 46, 96 💬 |
283 | ABT-494 | - | - | - | - | 7件: 41 41, 46, 49, 96, 97, 107, 271 💬 |
284 | ABT-494 15mg | - | - | - | - | 1件: 46 46 💬 |
285 | ABT-494 30mg | - | - | - | - | 1件: 46 46 💬 |
286 | ABY-035 | - | - | - | - | 1件: 271 271 💬 |
287 | Accelerated 30 minutes-infusion | - | - | - | - | 2件: 96 96, 97 💬 |
288 | Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
289 | Accordion Pill? Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
290 | Accordion Pill™ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
291 | ACE-011 | - | - | - | - | 1件: 86 86 💬 |
292 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 💬 |
293 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 💬 |
294 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 💬 |
295 | ACE-031 (Extension of cohort 1 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
296 | ACE-031 (Extension of cohort 2 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
297 | ACE-031 (Extension of cohort 3 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
298 | ACE-031 0.5 mg/kg q4wk | - | - | - | - | 1件: 113 113 💬 |
299 | ACE-031 1.0 mg/kg q2wk | - | - | - | - | 1件: 113 113 💬 |
300 | ACE-083 | - | - | - | - | 2件: 10 10, 113 💬 |
301 | ACER-002 (celiprolol) 200 mg BID | 1件: Celiprolol Celiprolol | 1件: Celiprolol
Celiprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 💬 |
302 | Acetaminophen Tablet 650mg | 1件: Acetaminophen Acetaminophen | 1件: Acetaminophen
Acetaminophen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
303 | Acetyl-L-carnitine 1000mg 2X per day for 3 months | 2件: Acetylcarnitine Acetylcarnitine, Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 298 298 💬 |
304 | ACH-0144471 | - | - | - | - | 2件: 62 62, 222 💬 |
305 | ACH-0144471 compresse | - | - | - | - | 1件: 222 222 💬 |
306 | ACH-0145228 | - | - | - | - | 1件: 62 62 💬 |
307 | ACHIM as solute (10^9 intestinal microbes/ml) | - | - | - | - | 1件: 51 51 💬 |
308 | ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable | - | - | - | - | 1件: 299 299 💬 |
309 | ACP-001 | - | - | - | - | 1件: 78 78 💬 |
310 | ACP-001 (TransCon hGH) | - | - | - | - | 1件: 78 78 💬 |
311 | ACP-011 | - | - | - | - | 1件: 78 78 💬 |
312 | ACR16 45 mg | - | - | - | - | 1件: 8 8 💬 |
313 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
314 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
315 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
316 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
317 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
318 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
319 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
320 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
321 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 💬 |
322 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
323 | ACT-293987 / JNJ-67896049 | - | - | - | - | 1件: 84 84 💬 |
324 | ACT-334441 | - | - | - | - | 1件: 49 49 💬 |
325 | ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
326 | ACT-385781A (Actelion Epoprostenol) | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
327 | ACT-434964 | - | - | - | - | 1件: 19 19 💬 |
328 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 61 61, 62 💬 |
329 | ACTHAR Gel 40 units twice weekly | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
330 | Acthar low dose (40 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
331 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 62 62, 66 💬 |
332 | Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | - | - | - | - | 1件: 6 6 💬 |
333 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
334 | Actonel Once a Week 35 mg film-coated tablets | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
335 | Actos 30 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
336 | Actos 45 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
337 | ACU-4429 | - | - | - | - | 1件: 301 301 💬 |
338 | ACZ885, 150mg/1.0ml | - | - | - | - | 2件: 266 266, 267 💬 |
339 | AD 452 | - | - | - | - | 1件: 46 46 💬 |
340 | AD 452 18 mg tablet | - | - | - | - | 1件: 46 46 💬 |
341 | AD 452 4.5 mg Tablet | - | - | - | - | 1件: 46 46 💬 |
342 | AD 452 9 mg tablet | - | - | - | - | 1件: 46 46 💬 |
343 | Ad26.COV2-S.02 | - | - | - | - | 1件: 299 299 💬 |
344 | Adalimumab (40mg) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
345 | Adalimumab (up to 9 months exposure) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
346 | Adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
347 | Adalimumab 40 mg eow or ew | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
348 | Adalimumab 40 mg sc every other week | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
349 | Adalimumab 40 mg subcutaneous (SC) every other week (EOW) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
350 | Adalimumab 40mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
351 | Adalimumab 40mg q2w | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
352 | Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
353 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
354 | ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
355 | ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
356 | ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
357 | ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
358 | Adempas 0.125 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
359 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
360 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
361 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
362 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
363 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
364 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
365 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
366 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
367 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
368 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
369 | Adeno-associated viral vector serotype 3B encoding shortened human ATP7B | - | - | - | - | 1件: 171 171 💬 |
370 | Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | - | - | - | - | 1件: 113 113 💬 |
371 | Adeno-associated viral vector serotype 9 containing the human N-acetyl-alpha-glucosaminidase gene | - | - | - | - | 1件: 19 19 💬 |
372 | Adeno-associated viral vector serotype 9 encoding human ATP7B | - | - | - | - | 1件: 171 171 💬 |
373 | Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA | 1件: Agalsidase alfa Agalsidase alfa | 1件: Agalsidase alfa
Agalsidase alfa
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
374 | Adeno-associated virus serotype 2/6 encoding Human Iduronate 2-sulfatase (hIDS) gene donor vector, SB-A6P-HNT Donor Vector | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
375 | Adeno-associated virus serotype 2/6 encoding human iduronidase (hIDUA) gene donor vector, SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
376 | Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector | - | - | - | - | 1件: 19 19 💬 |
377 | Adeno-associated virus serotype 2/6 encoding Right side-zinc finger nuclease (ZFN2), SB-A6P-ZRIGHT Vector | - | - | - | - | 1件: 19 19 💬 |
378 | Adeno-associated virus serotype 9 carrying the human fukutin-related protein and target sequence of the miR-208a | - | - | - | - | 1件: 113 113 💬 |
379 | ADS-001 | - | - | - | - | 1件: 231 231 💬 |
380 | Advagraf 0,5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
381 | Adverse Reactions of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
382 | Adverse Reactions of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
383 | ADVM-043 | - | - | - | - | 1件: 231 231 💬 |
384 | ADX-629 | - | - | - | - | 1件: 160 160 💬 |
385 | AER-901 Solution for Nebulization | - | - | - | - | 1件: 86 86 💬 |
386 | AEZS-130 (formerly ARD-07) | - | - | - | - | 1件: 78 78 💬 |
387 | AGS-009 | - | - | - | - | 1件: 49 49 💬 |
388 | AK106-001616 | 1件: AK106-001616 AK106-001616 | - | - | - | 1件: 46 46 💬 |
389 | AKBM-3031 | - | - | - | - | 1件: 49 49 💬 |
390 | AKR-501, YM-477 | - | - | - | - | 1件: 63 63 💬 |
391 | ALD518 monoclonal antibody (anti IL-6 mAb) | - | - | - | - | 1件: 46 46 💬 |
392 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
393 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
394 | ALK-001 | - | - | - | - | 1件: 301 301 💬 |
395 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
396 | All subjects will receive maraviroc 300mg orally twice a day for 6 weeks | 1件: Maraviroc Maraviroc | 1件: Maraviroc
Maraviroc
💬 | 1件: CCR5 CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 84 84 💬 |
397 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine | - | - | - | - | 1件: 2 2 💬 |
398 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy- | - | - | - | - | 1件: 2 2 💬 |
399 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
400 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
401 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
402 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
403 | ALN-60212 | - | - | - | - | 1件: 79 79 💬 |
404 | ALN-60519 | - | - | - | - | 1件: 254 254 💬 |
405 | ALN-61444 | - | - | - | - | 1件: 231 231 💬 |
406 | ALN-62643 | - | - | - | - | 2件: 62 62, 109 💬 |
407 | ALN-65585 | - | - | - | - | 1件: 234 234 💬 |
408 | ALRN-5281 0.015 mg/kg | - | - | - | - | 1件: 78 78 💬 |
409 | ALRN-5281 0.05 mg/kg | - | - | - | - | 1件: 78 78 💬 |
410 | ALRN-5281 0.15 mg/kg | - | - | - | - | 1件: 78 78 💬 |
411 | ALTH12-1:4 | - | - | - | - | 1件: 97 97 💬 |
412 | ALTH12-2:4 | - | - | - | - | 1件: 97 97 💬 |
413 | ALX-0061 | - | - | - | - | 2件: 46 46, 49 💬 |
414 | ALX-0061 150 mg/mL | - | - | - | - | 1件: 49 49 💬 |
415 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
416 | ALX-0081 | - | - | - | - | 1件: 64 64 💬 |
417 | ALX-009 | - | - | - | - | 1件: 299 299 💬 |
418 | ALX-0600 | - | - | - | - | 1件: 96 96 💬 |
419 | ALXN2040 (ACH-0144471) | - | - | - | - | 1件: 62 62 💬 |
420 | AM-01 | - | - | - | - | 1件: 51 51 💬 |
421 | Amantadine 300 mg | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
422 | AMB-05X | - | - | - | - | 1件: 85 85 💬 |
423 | AMBROSAN 60mg Tablets | - | - | - | - | 1件: 6 6 💬 |
424 | AMG 357 | - | - | - | - | 1件: 46 46 💬 |
425 | AMG 407 | - | - | - | - | 2件: 56 56, 107 💬 |
426 | AMG 623 | - | - | - | - | 1件: 49 49 💬 |
427 | AMG 827 350 MG | - | - | - | - | 1件: 96 96 💬 |
428 | AMG-407 | - | - | - | - | 2件: 56 56, 107 💬 |
429 | Amgevita 40 mg Injektionslösung im Fertigpen | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
430 | Amgevita 40 mg Injektionslösung in einer Fertigspritze | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
431 | Amgevita 40Mg Solution for Injection | - | - | - | - | 2件: 96 96, 97 💬 |
432 | ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | - | - | - | - | 1件: 156 156 💬 |
433 | ANG-3070 | - | - | - | - | 1件: 85 85 💬 |
434 | Anifrolumab 300 mg | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬 |
435 | Anti IL 6 mAb | - | - | - | - | 1件: 46 46 💬 |
436 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 💬 |
437 | Anti-CD20 small modular immunopharmaceutical, WYE-400087 | - | - | - | - | 1件: 46 46 💬 |
438 | Anti-IL-20 (109-0012) | 1件: Fletikumab Fletikumab | 1件: Fletikumab
Fletikumab
💬 | 1件: IL20 IL20 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
439 | Anti-IL-36R monoclonal antibody | - | - | - | - | 1件: 37 37 💬 |
440 | Anti-IL-6 mAb | - | - | - | - | 2件: 46 46, 96 💬 |
441 | Anti-Interleukin-6 Monoclonal | - | - | - | - | 1件: 46 46 💬 |
442 | Anti-Interleukin-6 Monoclonal Antibody | - | - | - | - | 2件: 46 46, 96 💬 |
443 | Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R. | - | - | - | - | 1件: 46 46 💬 |
444 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 💬 |
445 | AP1189, 60 mg | - | - | - | - | 1件: 46 46 💬 |
446 | Apomorphine 0.25% (2.5mg/ml) | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
447 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
448 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: Apraclonidine
Apraclonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
449 | Apremilast 30 mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 3件: 46 46, 56, 107 💬 |
450 | Apremilast 30mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 50 50 💬 |
451 | Apremilast tablet 30 mg BID | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 271 271 💬 |
452 | Apriso 0.375G ER CAP | - | - | - | - | 1件: 97 97 💬 |
453 | APRISO 375 mg extended-release capsules | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
454 | APT-1011 - 3 mg | - | - | - | - | 1件: 98 98 💬 |
455 | APT-1011 3 mg HS | - | - | - | - | 1件: 98 98 💬 |
456 | AR-42 | 1件: AR-42 AR-42 | - | - | - | 1件: 34 34 💬 |
457 | Arbaclofen placarbil 30 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
458 | Arbaclofen placarbil 45 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
459 | ARCOXIA 90 mg comprimidos recubiertos con película | - | - | - | - | 1件: 271 271 💬 |
460 | ARCT-032 | - | - | - | - | 1件: 299 299 💬 |
461 | ARD-3150 | - | - | - | - | 1件: 299 299 💬 |
462 | ARN-6039 | - | - | - | - | 1件: 13 13 💬 |
463 | ARO-ANG 3 Injection | - | - | - | - | 1件: 79 79 💬 |
464 | ARRY-371797 | - | - | - | - | 1件: 271 271 💬 |
465 | ARRY-371797, p38 inhibitor | - | - | - | - | 2件: 46 46, 271 💬 |
466 | ARRY-438162 | - | - | - | - | 1件: 46 46 💬 |
467 | ARRY-438162, MEK inhibitor | - | - | - | - | 1件: 46 46 💬 |
468 | ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
469 | Asacol 400 mg | - | - | - | - | 1件: 97 97 💬 |
470 | Asacol 400 mg (mesalamine) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
471 | Asacol 400 mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
472 | Asacol 400mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
473 | Asacol® 400 mg | - | - | - | - | 1件: 97 97 💬 |
474 | ASB-683699 | - | - | - | - | 1件: 13 13 💬 |
475 | ASF-1096 Cream 0.25% | - | - | - | - | 1件: 49 49 💬 |
476 | ASF-1096 Cream 0.5% | - | - | - | - | 1件: 49 49 💬 |
477 | ASF-1096 Cream 1.0% | - | - | - | - | 1件: 49 49 💬 |
478 | ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
479 | Aspirin 650mg Oral Capsule | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
480 | AT2221 65 mg Formulated Capsules | - | - | - | - | 1件: 256 256 💬 |
481 | ATI-450 | - | - | - | - | 2件: 46 46, 106 💬 |
482 | ATI-450 20mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
483 | ATI-450 50mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
484 | ATN-103 30 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
485 | Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet | 2件: Acetylcysteine Acetylcysteine, Atorvastatin | 2件: Acetylcysteine
Acetylcysteine
,
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 💬 |
486 | ATYR1923 1.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
487 | ATYR1923 3.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
488 | ATYR1923 5.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
489 | Autologous cardiac stem cells (JRM-001) | - | - | - | - | 2件: 210 210, 211 💬 |
490 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
491 | Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells | - | - | - | - | 1件: 51 51 💬 |
492 | AVALOX - 400 | - | - | - | - | 1件: 6 6 💬 |
493 | Avandia administration for 6-12 weeks | - | - | - | - | 1件: 265 265 💬 |
494 | AVCN583601 (3% Cannabidiol cream) | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 36 36 💬 |
495 | AVI-4658 | - | - | - | - | 1件: 113 113 💬 |
496 | AVI-4658 (Eteplirsen) | 1件: Eteplirsen Eteplirsen | 1件: Eteplirsen
Eteplirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
497 | AVI-4658 (PMO) | - | - | - | - | 1件: 113 113 💬 |
498 | AVI-4658 for Injection | - | - | - | - | 1件: 113 113 💬 |
499 | Aviptadil, 66 microgram/mL | 1件: Aviptadil Aviptadil | 1件: Aviptadil
Aviptadil
💬 | - | - | 1件: 85 85 💬 |
500 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
501 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
502 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
503 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
504 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
505 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
506 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
507 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
508 | AVP-923 | - | - | - | - | 3件: 2 2, 6, 13 💬 |
509 | AVP-923-45 | - | - | - | - | 1件: 6 6 💬 |
510 | AVR-RD-01 | - | - | - | - | 1件: 19 19 💬 |
511 | AVR-RD-02 | - | - | - | - | 1件: 19 19 💬 |
512 | AVX 470 | - | - | - | - | 1件: 97 97 💬 |
513 | Azathioprine (AZA) or 6-mercaptopurine (6-MP) | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 96 96, 97 💬 |
514 | Azathioprine / 6 Mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
515 | Azathioprine or 6-mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 96 96, 97 💬 |
516 | AZD3241 300 mg BID | - | - | - | - | 1件: 6 6 💬 |
517 | AZD3241 300mg | - | - | - | - | 1件: 17 17 💬 |
518 | AZD3241 600 mg BID | - | - | - | - | 1件: 6 6 💬 |
519 | AZD9567 40 mg | - | - | - | - | 1件: 46 46 💬 |
520 | AZP-3601 | - | - | - | - | 1件: 235 235 💬 |
521 | AZT/3TC | - | - | - | - | 1件: 265 265 💬 |
522 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 💬 |
523 | Baclofen ER Capsules (GRS) 30mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
524 | Baclofen ER Capsules (GRS) 40mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
525 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 💬 |
526 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
527 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 💬 |
528 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 💬 |
529 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 💬 |
530 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 💬 |
531 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 💬 |
532 | BAF312 4 mg tablet | - | - | - | - | 1件: 13 13 💬 |
533 | BAF312 4mg tablet | - | - | - | - | 1件: 50 50 💬 |
534 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
535 | Baricitinib 4 MG | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
536 | Batoclimab 340 mg SC bi-weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 💬 |
537 | Batoclimab 340 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 2件: 11 11, 14 💬 |
538 | Batoclimab 680 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 💬 |
539 | Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 14 14 💬 |
540 | BAY 63-2521 | - | - | - | - | 2件: 86 86, 88 💬 |
541 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 💬 |
542 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 💬 |
543 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
544 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
545 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
546 | BAY 63-2521 coated tablets 2 mg | - | - | - | - | 2件: 86 86, 88 💬 |
547 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
548 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
549 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
550 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
551 | BAY 63-2521 IR coated tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
552 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 💬 |
553 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
554 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
555 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
556 | BAY 63-2521 IR tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
557 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 💬 |
558 | BAY 63-2521 IR tablets 1 mg | - | - | - | - | 1件: 86 86 💬 |
559 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 💬 |
560 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 💬 |
561 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 💬 |
562 | BAY 63-2521 IR tablets 2.5 mg | - | - | - | - | 1件: 86 86 💬 |
563 | BAY 63-2521 Tablet | - | - | - | - | 1件: 86 86 💬 |
564 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
565 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
566 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
567 | BAY 63-2521 tablets 2 mg | - | - | - | - | 2件: 86 86, 88 💬 |
568 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
569 | BAY 79-4998 | - | - | - | - | 1件: 13 13 💬 |
570 | BAY q 3939 | - | - | - | - | 1件: 299 299 💬 |
571 | Bay Q 6256 | - | - | - | - | 1件: 86 86 💬 |
572 | BBP-418 | - | - | - | - | 1件: 113 113 💬 |
573 | BBP-671 | - | - | - | - | 2件: 245 245, 246 💬 |
574 | BBT-401-1S | - | - | - | - | 1件: 97 97 💬 |
575 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 💬 |
576 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 💬 |
577 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
578 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 💬 |
579 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 💬 |
580 | BCD-055 | - | - | - | - | 2件: 46 46, 271 💬 |
581 | BCD-063 | - | - | - | - | 1件: 13 13 💬 |
582 | BCD-085 | - | - | - | - | 2件: 93 93, 271 💬 |
583 | BCD-089 | - | - | - | - | 1件: 46 46 💬 |
584 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 💬 |
585 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 💬 |
586 | BCG20-0134 | - | - | - | - | 1件: 13 13 💬 |
587 | BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée | - | - | - | - | 1件: 94 94 💬 |
588 | Belantamab mafodotin 1.9 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
589 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
590 | Belantamab mafodotin 2.5 mg/kg (4 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
591 | Belantamab mafodotin 2.5 mg/kg (6 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
592 | Belimumab 4 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 💬 |
593 | Benlysta 400 mg powder for concentrate for solution for infusion | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 43 43, 49 💬 |
594 | Benlysta 400 mg powder for concentrate for solution for infusions | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
595 | Benlysta 400mg polvere per concentrato per soluzione per infusione | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 43 43 💬 |
596 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
597 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
598 | Beraprost Sodium 314d Modified Release Tablets | 1件: Beraprost Beraprost | 1件: Beraprost
Beraprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
599 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 💬 |
600 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
601 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
602 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
603 | Betaloc ZOK 100, 95 mg | - | - | - | - | 1件: 113 113 💬 |
604 | Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | 3件: Acetate Acetate, Betamethasone, Phosphate ion | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 💬 |
605 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 💬 |
606 | Bezafibrat Genericon retard 400 mg | - | - | - | - | 1件: 93 93 💬 |
607 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: Ursodiol
Ursodiol
,
Bezafibrate
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 💬 |
608 | Bezafibrate (INN 3968) | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 324 324 💬 |
609 | Bezafibrate 400 MG | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
610 | BF 2.649 | - | - | - | - | 1件: 6 6 💬 |
611 | BF 2.649 10 mg | - | - | - | - | 1件: 6 6 💬 |
612 | BF 2.649 20 mg | - | - | - | - | 1件: 6 6 💬 |
613 | BF 2.649 40 mg | - | - | - | - | 1件: 6 6 💬 |
614 | BF 2.649 5 mg | - | - | - | - | 1件: 6 6 💬 |
615 | BF2.649 | - | - | - | - | 1件: 6 6 💬 |
616 | BF2.649 (Pitolisant) | 1件: Pitolisant Pitolisant | 1件: Pitolisant
Pitolisant
💬 | 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
617 | BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
618 | BGP-014 | - | - | - | - | 1件: 97 97 💬 |
619 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 💬 |
620 | BGX-0214 | - | - | - | - | 1件: 46 46 💬 |
621 | BHT-3009 | - | - | - | - | 1件: 13 13 💬 |
622 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 💬 |
623 | BHT-3009 1.5 mg | - | - | - | - | 1件: 13 13 💬 |
624 | BHT-3009-01 | - | - | - | - | 1件: 13 13 💬 |
625 | BHV-0223 | - | - | - | - | 1件: 2 2 💬 |
626 | BHV-3241 | - | - | - | - | 1件: 17 17 💬 |
627 | BHV-4157 | - | - | - | - | 1件: 17 17 💬 |
628 | BI 1015550 9 mg Film Coated Tablet | - | - | - | - | 1件: 85 85 💬 |
629 | BI 443651 | - | - | - | - | 1件: 299 299 💬 |
630 | BI 655064 | - | - | - | - | 1件: 46 46 💬 |
631 | BI 655064 high dose | - | - | - | - | 1件: 46 46 💬 |
632 | BI 655064 low dose | - | - | - | - | 1件: 46 46 💬 |
633 | BI 655064 medium dose | - | - | - | - | 1件: 46 46 💬 |
634 | BI 655066 | - | - | - | - | 2件: 96 96, 271 💬 |
635 | BI 655066 10 mg/ml | - | - | - | - | 1件: 96 96 💬 |
636 | BI 655066 90 mg/ml | - | - | - | - | 2件: 96 96, 271 💬 |
637 | BI 655130 | - | - | - | - | 3件: 37 37, 96, 97 💬 |
638 | BI 685509 | - | - | - | - | 1件: 51 51 💬 |
639 | BI 695500 | - | - | - | - | 1件: 46 46 💬 |
640 | BI 695501 | - | - | - | - | 2件: 46 46, 96 💬 |
641 | BI 695501 Autoinjector | - | - | - | - | 1件: 46 46 💬 |
642 | BI 695501 Prefilled syringe | - | - | - | - | 1件: 46 46 💬 |
643 | BIA 3-202 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
644 | BIA 3-202 (200 mg) | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
645 | BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
646 | BIA 6-512 100 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
647 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
648 | BIA 6-512 200 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
649 | BIA 6-512 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
650 | BIA 6-512 25 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
651 | BIA 6-512 400 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
652 | BIA 6-512 50 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
653 | BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
654 | BIA 9-1067 (test) | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
655 | BIA 9-1067 15 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
656 | BIA 9-1067 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
657 | BIA 9-1067 30 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
658 | BIA 9-1067 5 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
659 | BIA 9-1067 micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
660 | BIA 9-1067 non-micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
661 | Bifidobacterium infantis 35624 | 1件: Bifidobacterium longum infantis Bifidobacterium longum infantis | - | - | - | 2件: 96 96, 97 💬 |
662 | BIIB 017 | - | - | - | - | 1件: 13 13 💬 |
663 | BINOCRIT*1SIR 40000UI/1ML | 1件: Erythropoietin Erythropoietin | - | - | - | 1件: 18 18 💬 |
664 | BMN 044 | - | - | - | - | 1件: 113 113 💬 |
665 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
666 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
667 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
668 | BMN 045 | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
669 | BMN 053 | - | - | - | - | 1件: 113 113 💬 |
670 | BMN 307 | - | - | - | - | 1件: 240 240 💬 |
671 | BMN165 40mg/day | - | - | - | - | 1件: 240 240 💬 |
672 | BMS-931699 | 1件: Lulizumab pegol Lulizumab pegol | - | - | - | 3件: 49 49, 53, 160 💬 |
673 | BMS-936557 | - | - | - | - | 2件: 96 96, 97 💬 |
674 | BMS-936557 (Anti-IP-10 Antibody) | - | - | - | - | 1件: 96 96 💬 |
675 | BMS-945429 | 1件: Clazakizumab Clazakizumab | 1件: Clazakizumab
Clazakizumab
💬 | - | - | 2件: 46 46, 96 💬 |
676 | BMS-986004 | - | - | - | - | 1件: 63 63 💬 |
677 | BMS-986004 1500 mg IV | - | - | - | - | 1件: 63 63 💬 |
678 | BMS-986004 225 mg IV | - | - | - | - | 1件: 63 63 💬 |
679 | BMS-986004 675 mg IV | - | - | - | - | 1件: 63 63 💬 |
680 | BMS-986004 75 mg IV | - | - | - | - | 1件: 63 63 💬 |
681 | BMS-986020 | 1件: BMS-986020 BMS-986020 | - | - | - | 2件: 51 51, 85 💬 |
682 | BMS-986089 | - | - | - | - | 1件: 113 113 💬 |
683 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
684 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
685 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
686 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
687 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
688 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
689 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
690 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
691 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
692 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
693 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
694 | BMS-986104 | 1件: BMS-986104 BMS-986104 | - | - | - | 1件: 46 46 💬 |
695 | BMS-986142 | 1件: BMS-986142 BMS-986142 | - | - | - | 3件: 46 46, 53, 160 💬 |
696 | BMS-986142 200mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 💬 |
697 | BMS-986142 350mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 💬 |
698 | BMS-986165 | - | - | - | - | 3件: 49 49, 96, 97 💬 |
699 | BMS-986165 Capsule | - | - | - | - | 1件: 49 49 💬 |
700 | BMS-986165 Tablet | - | - | - | - | 1件: 49 49 💬 |
701 | BMS-986166 | - | - | - | - | 1件: 97 97 💬 |
702 | BMS-986168 | 1件: Gosuranemab Gosuranemab | 1件: Gosuranemab
Gosuranemab
💬 | 1件: MAPT MAPT 💬 | 4件: Alzheimer disease Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 5 5 💬 |
703 | BMS-986184 | - | - | - | - | 1件: 97 97 💬 |
704 | BMS-986195 | 1件: Branebrutinib Branebrutinib | 1件: Branebrutinib
Branebrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 3件: 46 46, 49, 53 💬 |
705 | BMS-986251 | - | - | - | - | 2件: 46 46, 271 💬 |
706 | BMS-986256 | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
707 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
708 | BMS-986278 | - | - | - | - | 1件: 85 85 💬 |
709 | BMS-986325 | - | - | - | - | 1件: 53 53 💬 |
710 | Bosentan 62.5 mg | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
711 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
712 | BPLG-003 | - | - | - | - | 1件: 78 78 💬 |
713 | BPS-314d-MR | - | - | - | - | 1件: 86 86 💬 |
714 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 💬 |
715 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
716 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
717 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
718 | BRL-049653 | - | - | - | - | 1件: 46 46 💬 |
719 | BRX-345 | - | - | - | - | 2件: 2 2, 15 💬 |
720 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 💬 |
721 | BT051 3200 mg | - | - | - | - | 1件: 97 97 💬 |
722 | Budenofalk 3mg | - | - | - | - | 2件: 93 93, 97 💬 |
723 | Budenofalk 3mg gastro-resistant capsules | - | - | - | - | 1件: 96 96 💬 |
724 | Budenofalk 9mg gastro-resistant granules | - | - | - | - | 1件: 96 96 💬 |
725 | Budesonide ( Zentacort Capsules 3mg ) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
726 | Budesonide (6 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
727 | Budesonide (9 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
728 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
729 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
730 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
731 | Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
732 | Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
733 | Budesonide 9 mg capsules, hard (BUX-PV) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
734 | Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
735 | Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
736 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
737 | Budesonide MMX 6 mg Tablet | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
738 | Budesonide MMX® 6 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
739 | Budesonide MMX® 9 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
740 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
741 | Budesonide-MMX® 6 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
742 | Budesonide-MMX® 9 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
743 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
744 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
745 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 💬 |
746 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 💬 |
747 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 3件: Epinephrine
Epinephrine
,
Clonidine
,
Bupivacaine
💬 | 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬 |
748 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
749 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 2件: 19 19, 65 💬 |
750 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 💬 |
751 | C-028380 | - | - | - | - | 1件: 106 106 💬 |
752 | C326, IL-6 Inhibitory Avimer protein | - | - | - | - | 1件: 96 96 💬 |
753 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
754 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
755 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
756 | CALY-002 | - | - | - | - | 1件: 98 98 💬 |
757 | CAM-3001 | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
758 | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | - | - | - | - | 1件: 107 107 💬 |
759 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
760 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
761 | Capsules with 160 mg Teavigo (at least 94% EGCG) | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 13 13 💬 |
762 | Carbidopa 65 mg capsule | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
763 | Carbidopa-4'-Monophosphate | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
764 | Carbomer 974P | 2件: Carbomer Carbomer, Carbopol 974P | - | - | - | 1件: 53 53 💬 |
765 | Carbon-14 BIA 28-6156 | 2件: Activated charcoal Activated charcoal, BIA | - | - | - | 1件: 6 6 💬 |
766 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
767 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
768 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
769 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 💬 |
770 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
771 | CAT-354 | - | - | - | - | 1件: 97 97 💬 |
772 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
773 | CB-01-02 | - | - | - | - | 1件: 97 97 💬 |
774 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 💬 |
775 | CBP-307 | - | - | - | - | 1件: 97 97 💬 |
776 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
777 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
778 | CC-4047 | - | - | - | - | 2件: 28 28, 51 💬 |
779 | CC-90001 | - | - | - | - | 1件: 85 85 💬 |
780 | CC-930 | - | - | - | - | 1件: 85 85 💬 |
781 | CC-93538 | - | - | - | - | 1件: 98 98 💬 |
782 | CC-99677 | - | - | - | - | 1件: 271 271 💬 |
783 | CC-99677 30mg Capsule | - | - | - | - | 1件: 271 271 💬 |
784 | CC-99677 60mg Capsule | - | - | - | - | 1件: 271 271 💬 |
785 | CCD 1042, MD 9150000, Mepalon 1042, SPT316 | - | - | - | - | 2件: 152 152, 206 💬 |
786 | CCD 1042, MD 9150000, Mepalon 1042, SPT3162 | - | - | - | - | 1件: 152 152 💬 |
787 | CCP-020 | - | - | - | - | 1件: 36 36 💬 |
788 | CCP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
789 | CCX 354 | - | - | - | - | 1件: 46 46 💬 |
790 | CCX 354-C | - | - | - | - | 1件: 46 46 💬 |
791 | CCX-354 | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 💬 |
792 | CCX-354-C | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 💬 |
793 | CD-4 guided therapy interruption | - | - | - | - | 1件: 265 265 💬 |
794 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 💬 |
795 | CDP870 400mg | - | - | - | - | 1件: 46 46 💬 |
796 | CDX 6114 | - | - | - | - | 1件: 240 240 💬 |
797 | Celecoxib 400 milligrams | 1件: Celecoxib Celecoxib | 1件: Celecoxib
Celecoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
798 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
799 | Cenerimod 4 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
800 | CEP-33457 | - | - | - | - | 1件: 49 49 💬 |
801 | CER-001 | - | - | - | - | 1件: 79 79 💬 |
802 | CERC-006 | - | - | - | - | 1件: 278 278 💬 |
803 | Cerezyme 400 Units Powder for concentrate for solution for infusion | 1件: Imiglucerase Imiglucerase | 1件: Imiglucerase
Imiglucerase
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
804 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
805 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
806 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
807 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
808 | Certolizumab Pegol (CZP) 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
809 | Certolizumab pegol 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
810 | CFZ533 active - Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
811 | CFZ533 active -Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
812 | CH-4051 | - | - | - | - | 1件: 46 46 💬 |
813 | CHF 6333 | - | - | - | - | 1件: 299 299 💬 |
814 | Chimeric murine human anti-IL-6 monoclonal antibody | - | - | - | - | 1件: 331 331 💬 |
815 | Chinese herbal concoction twice a day for 6 months | - | - | - | - | 1件: 60 60 💬 |
816 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
817 | Cholecalciferol 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
818 | CHS-0214 | - | - | - | - | 1件: 46 46 💬 |
819 | CI-984 | - | - | - | - | 1件: 75 75 💬 |
820 | CI-984, 17AA70, PD 132301-2 | - | - | - | - | 1件: 81 81 💬 |
821 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
822 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
823 | CIPROXIN*6CPR RIV 500MG | - | - | - | - | 1件: 299 299 💬 |
824 | Cis-4-Hydroxy-L-Proline | 1件: Proline Proline | 1件: Proline
Proline
💬 | - | - | 1件: 94 94 💬 |
825 | CITICOLIN*1G/4ML IM IV 5 F | - | - | - | - | 1件: 6 6 💬 |
826 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
827 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
828 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
829 | CK-3773274 | - | - | - | - | 1件: 58 58 💬 |
830 | CK-3773274 (10 - 30 mg) | - | - | - | - | 1件: 58 58 💬 |
831 | CK-3773274 (5 - 15 mg) | - | - | - | - | 1件: 58 58 💬 |
832 | CK-3773274 (5 - 20 mg) | - | - | - | - | 1件: 58 58 💬 |
833 | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg) | - | - | - | - | 1件: 58 58 💬 |
834 | CK-3773274 - Granules in Capsule | - | - | - | - | 1件: 58 58 💬 |
835 | CK-3773274 - Tablets | - | - | - | - | 1件: 58 58 💬 |
836 | CKD-374 5mg Tab. | - | - | - | - | 1件: 46 46 💬 |
837 | Cladribine 3.5 mg/kg | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
838 | Clarithromycin (Not used as of 4/2020) | 1件: Clarithromycin Clarithromycin | 1件: Clarithromycin
Clarithromycin
💬 | - | - | 1件: 6 6 💬 |
839 | Clipper 30 cpr 5mg R.M. | - | - | - | - | 1件: 97 97 💬 |
840 | CLIPPER*30CPR 5MG R.M. | - | - | - | - | 1件: 97 97 💬 |
841 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 💬 |
842 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
843 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 💬 |
844 | CLTX-305 | - | - | - | - | 1件: 235 235 💬 |
845 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 💬 |
846 | CNSA-001 | - | - | - | - | 1件: 240 240 💬 |
847 | CNT-02 | - | - | - | - | 1件: 160 160 💬 |
848 | CNTO 1959 + MTX (Group 4) | - | - | - | - | 1件: 46 46 💬 |
849 | CNTO 328 | - | - | - | - | 1件: 331 331 💬 |
850 | CNTO 6785 100 mg | - | - | - | - | 1件: 46 46 💬 |
851 | CNTO 6785 15 mg | - | - | - | - | 1件: 46 46 💬 |
852 | CNTO 6785 200 mg | - | - | - | - | 1件: 46 46 💬 |
853 | CNTO 6785 50 mg | - | - | - | - | 1件: 46 46 💬 |
854 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 💬 |
855 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
856 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
857 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
858 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 💬 |
859 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
860 | Cohort 3 2.25 g | - | - | - | - | 1件: 240 240 💬 |
861 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
862 | COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 💬 |
863 | COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML | - | - | - | - | 1件: 299 299 💬 |
864 | Combination Product: EGCG 300 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
865 | Combination Product: EGCG 300 mg + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
866 | Combination Product: EGCG 600 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
867 | Combination Product: EGCG 600 mg + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
868 | Combination Product: L-dopa 35 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
869 | Combivir (zidovudine [AZT] / lamivudine [3TC]) | 2件: Lamivudine Lamivudine, Zidovudine | 2件: Lamivudine
Lamivudine
,
Zidovudine
💬 | - | - | 1件: 265 265 💬 |
870 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
871 | COMTAN 200* 60 CPR 200 MG | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
872 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
873 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 💬 |
874 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
875 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
876 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
877 | Copaxone 40 mg/ml | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
878 | Copaxone 40 mg/ml solution for injection, pre-filled syringe | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
879 | COPPER (64CU) CHLORIDE | 2件: Chloride ion Chloride ion, Copper | - | - | - | 1件: 171 171 💬 |
880 | COR-003 | - | - | - | - | 1件: 75 75 💬 |
881 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
882 | CortimentMMX 9 mg | - | - | - | - | 1件: 97 97 💬 |
883 | Cosentyx 300 mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
884 | Cosentyx 300mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
885 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
886 | CP 690,550 | - | - | - | - | 1件: 46 46 💬 |
887 | CP 690550 MR | - | - | - | - | 1件: 46 46 💬 |
888 | CP- 690 550 | - | - | - | - | 1件: 97 97 💬 |
889 | CP-461 | - | - | - | - | 1件: 96 96 💬 |
890 | CP-690, 550 - 10 | - | - | - | - | 1件: 46 46 💬 |
891 | CP-690, 550-10 | - | - | - | - | 2件: 97 97, 107 💬 |
892 | CP-690,500 5 mg | - | - | - | - | 1件: 97 97 💬 |
893 | CP-690,55-10 | - | - | - | - | 1件: 46 46 💬 |
894 | CP-690,550 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
895 | CP-690,550 (tasocitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
896 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 💬 |
897 | CP-690,550 + methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
898 | CP-690,550 10 mg | - | - | - | - | 1件: 97 97 💬 |
899 | CP-690,550 – 10 | - | - | - | - | 1件: 46 46 💬 |
900 | CP-690,550-10 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
901 | CP-690-550 | - | - | - | - | 1件: 46 46 💬 |
902 | CP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
903 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 💬 |
904 | CR 3 | - | - | - | - | 1件: 46 46 💬 |
905 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 💬 |
906 | CRC3357, ZK-355322, Leukoton | - | - | - | - | 1件: 299 299 💬 |
907 | CRD-TMH-001 | - | - | - | - | 1件: 113 113 💬 |
908 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
909 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
910 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
911 | Creon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
912 | CRx-102 (2.7/360) | - | - | - | - | 1件: 46 46 💬 |
913 | CS-0777 tablets | - | - | - | - | 1件: 13 13 💬 |
914 | CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST) | - | - | - | - | 1件: 19 19 💬 |
915 | CTX-4430 | - | - | - | - | 1件: 299 299 💬 |
916 | Cu-64 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
917 | Cudetaxestat (BLD-0409) | - | - | - | - | 1件: 85 85 💬 |
918 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
919 | CVT-301 | - | - | - | - | 1件: 6 6 💬 |
920 | CVT-301 (Dose Level 1) | - | - | - | - | 1件: 6 6 💬 |
921 | CVT-301 (Dose Level 2) | - | - | - | - | 1件: 6 6 💬 |
922 | CVT-301 35mg | - | - | - | - | 1件: 6 6 💬 |
923 | CVT-301 50mg | - | - | - | - | 1件: 6 6 💬 |
924 | CVT-301 High Dose | - | - | - | - | 1件: 6 6 💬 |
925 | CVT-301 Low Dose | - | - | - | - | 1件: 6 6 💬 |
926 | CVT-301, LIP | - | - | - | - | 1件: 6 6 💬 |
927 | CVXL-0107 | - | - | - | - | 1件: 6 6 💬 |
928 | CX-016492 | - | - | - | - | 1件: 245 245 💬 |
929 | CX-017950 | - | - | - | - | 1件: 245 245 💬 |
930 | CX-4945 oral formulation | - | - | - | - | 1件: 331 331 💬 |
931 | Cyclophosphamide 30 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
932 | Cyclophosphamide 40 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
933 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
934 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
935 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 💬 |
936 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
937 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
938 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
939 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
940 | D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
941 | D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
942 | D.3.2 Product code where applicable13: | - | - | - | - | 1件: 193 193 💬 |
943 | D.3.6.2 - dose massima specificare: giornaliera | - | - | - | - | 1件: 86 86 💬 |
944 | D.3.6.2.1 - valore: 45 / 0.45 mg/ml | - | - | - | - | 1件: 97 97 💬 |
945 | D.3.6.2.1 - valore: 5 o 10 mg/kg | - | - | - | - | 1件: 97 97 💬 |
946 | D9421-C capsule 3 mg | - | - | - | - | 1件: 96 96 💬 |
947 | D9421-C, 9mg | - | - | - | - | 1件: 96 96 💬 |
948 | DA-9701 | - | - | - | - | 1件: 6 6 💬 |
949 | DA-9805 45mg | - | - | - | - | 1件: 6 6 💬 |
950 | DA-9805 90mg | - | - | - | - | 1件: 6 6 💬 |
951 | Dacortín 30mg | - | - | - | - | 1件: 222 222 💬 |
952 | Darifenacin (BAY79-4998) | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
953 | DAS-001 | - | - | - | - | 1件: 11 11 💬 |
954 | Dazucorilant 300 mg | - | - | - | - | 1件: 2 2 💬 |
955 | DB adalimumab 40 mg eow | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
956 | DB adalimumab 40 mg ew | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
957 | Deferiprone 30mg | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
958 | Deferiprone 600 mg delayed release tablet | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
959 | DEFLAN*10CPR 6MG | - | - | - | - | 1件: 113 113 💬 |
960 | Deflazacort 6 mg Tablets | 1件: Deflazacort Deflazacort | 1件: Deflazacort
Deflazacort
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
961 | Dehydroepiandrosterone 100 and 400 mg | 1件: Prasterone Prasterone | 1件: Prasterone
Prasterone
💬 | 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 113 113 💬 |
962 | Dekristol 20.000 ie | - | - | - | - | 1件: 96 96 💬 |
963 | Dekristol® 400-Tabletten | - | - | - | - | 1件: 13 13 💬 |
964 | Dekristol®-Tablette 1 (400 IE) | - | - | - | - | 1件: 13 13 💬 |
965 | Delayed Release 6 mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
966 | Delayed Release 6MP or Calcitriol vs. Purinethol | 1件: Calcitriol Calcitriol | 1件: Calcitriol
Calcitriol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
967 | Delta-9-tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 3件: 8 8, 13, 36 💬 |
968 | Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 8 8 💬 |
969 | DEPALGOS*20+325MG 28CPR RP | - | - | - | - | 1件: 46 46 💬 |
970 | Depo-Medrol 40Mg/Ml Suspension for Injection | - | - | - | - | 1件: 70 70 💬 |
971 | Depot leuprolide acetate 3.75 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 51 51 💬 |
972 | Descartes-08 | - | - | - | - | 1件: 11 11 💬 |
973 | Desmopressine nasal spray 10 mg/ml, flacon 60 doses | 1件: Desmopressin Desmopressin | 1件: Desmopressin
Desmopressin
💬 | 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 225 225 💬 |
974 | Desmotabs® 0,2 mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
975 | Desmotabs® 0,2mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
976 | Dexamethasone (4 cycles) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
977 | Dexamethasone (50mg 1dd6, 3 consecutive days/month) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬 |
978 | Dexamethasone 0,1 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
979 | Dexamethasone 0,5mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
980 | Dexamethasone 0.5mg Tablet | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
981 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
982 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
983 | Dexamethasone 4 mg JENAPHARM | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
984 | Dexamethasone, 40 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
985 | Dexmedetomidine 3 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬 |
986 | Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 💬 |
987 | DIBASE*IM OS 2F 1ML 300000UI/M | - | - | - | - | 1件: 46 46 💬 |
988 | Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 107 107 💬 |
989 | Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 96 96 💬 |
990 | Digoxin 0.25 mg | 1件: Digoxin Digoxin | 1件: Digoxin
Digoxin
💬 | 4件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4 💬 | 18件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
991 | Diovan 40 mg | 1件: Valsartan Valsartan | 1件: Valsartan
Valsartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
992 | DIURF-006 | - | - | - | - | 1件: 81 81 💬 |
993 | Dl-3-n-butylphthalide (NBP) | 1件: Butylphthalide Butylphthalide | - | - | - | 1件: 22 22 💬 |
994 | Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO] | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: Lamivudine
Lamivudine
,
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
995 | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | 4件: Doravirine Doravirine, Lamivudine, Tenofovir, Tenofovir disoproxil | 3件: Lamivudine
Lamivudine
,
Tenofovir
,
Doravirine
💬 | - | - | 1件: 265 265 💬 |
996 | Dose level 3 | - | - | - | - | 1件: 46 46 💬 |
997 | Dose level 4 | - | - | - | - | 1件: 46 46 💬 |
998 | Dose of 60 mg/kg alpha1-proteinase inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
999 | Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
1000 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: Gadoteric acid
Gadoteric acid
💬 | - | - | 1件: 13 13 💬 |
1001 | Doxycycline 100-200mg capsules daily for 6 months | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 167 167 💬 |
1002 | Dulaglutide 0.75Mg/0.5Ml Inj Pen | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1003 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 💬 |
1004 | Dupilumab 300Mg Solution for Injection | 1件: Dupilumab Dupilumab | 1件: Dupilumab
Dupilumab
💬 | 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 51 51 💬 |
1005 | DUR-928 | - | - | - | - | 1件: 94 94 💬 |
1006 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
1007 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | 1件: 63 63 💬 |
1008 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
1009 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 💬 |
1010 | EC 3.1.3.1 | - | - | - | - | 1件: 46 46 💬 |
1011 | EDG-5506 Dose 3 | - | - | - | - | 1件: 113 113 💬 |
1012 | EDG-5506 Dose 4 | - | - | - | - | 1件: 113 113 💬 |
1013 | EDP-305 | - | - | - | - | 1件: 93 93 💬 |
1014 | EDP-305 Dose 1 | - | - | - | - | 1件: 93 93 💬 |
1015 | EDP-305 Dose 2 | - | - | - | - | 1件: 93 93 💬 |
1016 | Efficacy of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
1017 | Efficacy of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
1018 | EFI/ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
1019 | Efzofitimod 3 mg/kg | - | - | - | - | 1件: 84 84 💬 |
1020 | Elelyso 60 units/kg | 1件: Taliglucerase alfa Taliglucerase alfa | 1件: Taliglucerase alfa
Taliglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1021 | Eltrombopag olamine (SB-497115-GR) | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 💬 |
1022 | ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) | - | - | - | - | 1件: 299 299 💬 |
1023 | ELX-02 | 1件: ELX-02 ELX-02 | - | - | - | 3件: 19 19, 218, 299 💬 |
1024 | EMEA/H/C/000109 | - | - | - | - | 1件: 203 203 💬 |
1025 | EMEA/H/C/000125 | - | - | - | - | 1件: 299 299 💬 |
1026 | EMEA/H/C/000240 | - | - | - | - | 2件: 96 96, 97 💬 |
1027 | EMEA/H/C/000481 | - | - | - | - | 1件: 97 97 💬 |
1028 | EMEA/H/C/000638 | - | - | - | - | 1件: 113 113 💬 |
1029 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 💬 |
1030 | EMEA/H/C/000712 | - | - | - | - | 1件: 227 227 💬 |
1031 | EMEA/H/C/002576 | - | - | - | - | 1件: 96 96 💬 |
1032 | EMEA/H/C/002778 | - | - | - | - | 1件: 96 96 💬 |
1033 | EMEA/H/C/004214 | - | - | - | - | 1件: 46 46 💬 |
1034 | EMIXUSTAT HYDROCHLORIDE (ACU-4429) | 1件: Emixustat Emixustat | 1件: Emixustat
Emixustat
💬 | - | - | 1件: 301 301 💬 |
1035 | ENB-0040 | - | - | - | - | 1件: 172 172 💬 |
1036 | ENBREL*BB SC 4FL 25MG 1ML+4SIR | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1037 | ENBREL*SC 4FL 25MG+4SIR 1ML | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 60, 285 💬 |
1038 | ENBREL*SC 4FL 50MG+4SIR+4AGHI+ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1039 | ENBREL*SC 4SIR 25MG 0,5ML+8TAM | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1040 | ENBREL*SC 4SIR 50MG 1ML+8TAMP | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1041 | ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA | - | - | - | - | 1件: 51 51 💬 |
1042 | ENDOPROST 0,05MG/0,5ML 1F | - | - | - | - | 1件: 51 51 💬 |
1043 | ENDOPROST 50*INFUS 1F 0,050MG/ | - | - | - | - | 1件: 51 51 💬 |
1044 | Endothelin-3 | - | - | - | - | 1件: 86 86 💬 |
1045 | Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) | - | - | - | - | 1件: 46 46 💬 |
1046 | ENT-01 | - | - | - | - | 1件: 6 6 💬 |
1047 | Entacapone 400mg oral dose | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
1048 | EnteraBio's Oral Parathyroid Hormone (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1049 | Entocort EC® 3 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1050 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFU | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1051 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
1052 | ENTYVIO - 300 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1053 | Entyvio 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1054 | Entyvio 300mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1055 | Eosinophilic Esophagitis (EoE) Food introduction-3rd dose | - | - | - | - | 1件: 98 98 💬 |
1056 | Epanova™ (Omega-3 Free Fatty Acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 96 96 💬 |
1057 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 💬 |
1058 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
1059 | EPI-743 400mg | - | - | - | - | 1件: 6 6 💬 |
1060 | Epigallocatechin-3-gallate | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 3件: 8 8, 28, 85 💬 |
1061 | Epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 2件: 28 28, 85 💬 |
1062 | Epilim Chrono 300 Controlled Released tablets | - | - | - | - | 1件: 256 256 💬 |
1063 | Epratuzumab 400 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1064 | Epratuzumab 600 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1065 | EPREX IV SC 1FL 1ML 40000 UI | - | - | - | - | 1件: 2 2 💬 |
1066 | EPREX*1FL 40000UI/ML 1ML | - | - | - | - | 1件: 18 18 💬 |
1067 | EPREX*1SIR 40000UI/ML 1ML | - | - | - | - | 2件: 2 2, 18 💬 |
1068 | ERB-041 | - | - | - | - | 3件: 46 46, 96, 226 💬 |
1069 | ERX-963 | - | - | - | - | 1件: 113 113 💬 |
1070 | Etanercept (50mg per week, for 4 weeks) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1071 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
1072 | ETHANOL (96 PER CENT) | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 279 279 💬 |
1073 | Ethanol 96% Gel | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 279 279 💬 |
1074 | Ethanol 98% Solution | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 279 279 💬 |
1075 | Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) | - | - | - | - | 1件: 6 6 💬 |
1076 | Etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1077 | Etoricoxib 90 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1078 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
1079 | EU/1/03/256/001 | - | - | - | - | 1件: 107 107 💬 |
1080 | EU/1/03/268/002 | - | - | - | - | 1件: 96 96 💬 |
1081 | EU/1/06/362/003: 5µg (1 pen) | - | - | - | - | 1件: 193 193 💬 |
1082 | EU/1/07/389/001 | - | - | - | - | 1件: 107 107 💬 |
1083 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 💬 |
1084 | EU/1/14/980/002 | - | - | - | - | 1件: 269 269 💬 |
1085 | EU/1/14/980/003 | - | - | - | - | 1件: 269 269 💬 |
1086 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 💬 |
1087 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 💬 |
1088 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 💬 |
1089 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 💬 |
1090 | EU/1/99/116/003 | - | - | - | - | 1件: 96 96 💬 |
1091 | EU/1/99/126/001 | - | - | - | - | 1件: 107 107 💬 |
1092 | EU/1/99/126/017 | - | - | - | - | 1件: 46 46 💬 |
1093 | EU/1/99/126/020 | - | - | - | - | 1件: 46 46 💬 |
1094 | EU/3/13/1208 orphan | - | - | - | - | 1件: 301 301 💬 |
1095 | EU1/97/031-032 | - | - | - | - | 1件: 18 18 💬 |
1096 | EU1/97/031/031-032 | - | - | - | - | 1件: 18 18 💬 |
1097 | EUR-1008 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1098 | EVP-0334 | - | - | - | - | 1件: 127 127 💬 |
1099 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 💬 |
1100 | EXCL-100, 600 MG Oral Tablet | - | - | - | - | 1件: 85 85 💬 |
1101 | Exelon 3,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1102 | Exelon 4.6 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1103 | Exelon 6,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1104 | Exelon 9.5 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1105 | EXG001-307 injection | - | - | - | - | 1件: 3 3 💬 |
1106 | EXN-32 | - | - | - | - | 1件: 6 6 💬 |
1107 | EXN-32 (CARBIDOPA E LEVODOPA) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1108 | EXN-44 | - | - | - | - | 1件: 6 6 💬 |
1109 | EXN-44(LEVODOPA) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1110 | F-18 3F4AP | - | - | - | - | 1件: 13 13 💬 |
1111 | FABRAZYME - 35 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1112 | Fabrazyme 35 mg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1113 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1114 | FANG(30) | - | - | - | - | 1件: 46 46 💬 |
1115 | Fanhdi 25 UI FVIII-30 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1116 | Fanhdi 50 UI FVIII-60 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1117 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: Fasudil
Fasudil
💬 | 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1118 | FCX-007 | - | - | - | - | 1件: 36 36 💬 |
1119 | FCX-013 | - | - | - | - | 1件: 51 51 💬 |
1120 | FE 992097 | - | - | - | - | 1件: 193 193 💬 |
1121 | FE 999301 | - | - | - | - | 2件: 96 96, 97 💬 |
1122 | Ferrous sulfate 325mg | 1件: Sulfate ion Sulfate ion | - | - | - | 1件: 299 299 💬 |
1123 | FG-3019 | - | - | - | - | 3件: 85 85, 113, 222 💬 |
1124 | FG-3019 10mg/mL in 10 mL vials | - | - | - | - | 1件: 85 85 💬 |
1125 | Fibrovein 3% | - | - | - | - | 1件: 279 279 💬 |
1126 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1127 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1128 | Fipamezole hydrochloride 30 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1129 | Fipamezole hydrochloride 60 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1130 | Fipamezole hydrochloride 90 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1131 | Firategrast 300 mg | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1132 | FISH OIL, RICH IN OMEGA-3-ACIDS | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
1133 | FISH OIL,RICH IN OMEGA 3 ACIDS | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 💬 |
1134 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1135 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1136 | Florence 30 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1137 | Florence 60 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1138 | Florence 90 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1139 | Fludarabine phosphate 30 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
1140 | Fludarabine phosphate 40 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
1141 | FLUIMUCIL*20CPR EFF 600MG | - | - | - | - | 2件: 94 94, 298 💬 |
1142 | Fluimucil® 600 mg effervescent tablets | - | - | - | - | 1件: 85 85 💬 |
1143 | FMP-30 | - | - | - | - | 1件: 53 53 💬 |
1144 | FolateScan (Technetium Tc 99mEC20) | - | - | - | - | 4件: 13 13, 46, 49, 96 💬 |
1145 | Foliglurax 30 mg (treatment B) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 💬 |
1146 | FORLAX 4 g, poudre pour solution buvable en sachet | - | - | - | - | 1件: 299 299 💬 |
1147 | Fortecortin Inject 40 mg Amp. | - | - | - | - | 1件: 65 65 💬 |
1148 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 💬 |
1149 | Fospropofol (Lusedra®) 6.5 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1150 | FP-CYA-050 | - | - | - | - | 1件: 97 97 💬 |
1151 | FP-CYA-053 | - | - | - | - | 1件: 97 97 💬 |
1152 | FPF 300 (thalidomide) | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 💬 |
1153 | FRISIUM*30CPS 10MG | - | - | - | - | 1件: 140 140 💬 |
1154 | FRM-0334 | - | - | - | - | 1件: 127 127 💬 |
1155 | Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody | - | - | - | - | 1件: 13 13 💬 |
1156 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 💬 |
1157 | GA 40 mg/mL | - | - | - | - | 1件: 13 13 💬 |
1158 | GA Depot 40 mg | - | - | - | - | 1件: 13 13 💬 |
1159 | GA Depot 40mg once monthly | - | - | - | - | 1件: 13 13 💬 |
1160 | Ga-68-DOTA-NOC | - | - | - | - | 1件: 84 84 💬 |
1161 | Gabapentin (neurontin® capsule 300mg) treatment | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
1162 | Gabapentine 300mg | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1163 | Gaboxadol (HLX-0206) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
1164 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1165 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1166 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1167 | Gadovist 1.0 mmol/ml Injektionslösung | 1件: Gadobutrol Gadobutrol | 1件: Gadobutrol
Gadobutrol
💬 | - | - | 1件: 13 13 💬 |
1168 | Gallium-68 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
1169 | Gallium-68-DOTA-N-Octreotide | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
1170 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3beta-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1171 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1172 | GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO | 1件: Obinutuzumab Obinutuzumab | 1件: Obinutuzumab
Obinutuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
1173 | GB-0998 | - | - | - | - | 1件: 50 50 💬 |
1174 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 💬 |
1175 | GB224 30mg | - | - | - | - | 1件: 46 46 💬 |
1176 | GBT440 300 mg capsule | - | - | - | - | 1件: 85 85 💬 |
1177 | GBT440 300 mg tablet | - | - | - | - | 1件: 85 85 💬 |
1178 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 💬 |
1179 | GCK 300 mg | - | - | - | - | 1件: 46 46 💬 |
1180 | GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1181 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1182 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1183 | GED-0301 | - | - | - | - | 2件: 96 96, 97 💬 |
1184 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1185 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1186 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1187 | Gene Therapy-vMCO-010 | - | - | - | - | 1件: 301 301 💬 |
1188 | Gene-Activated Human Glucocerebrosidase 400U/vial | - | - | - | - | 1件: 19 19 💬 |
1189 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 💬 |
1190 | Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1191 | Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1192 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 💬 |
1193 | Genotropin (PN-180,307) Somatropin | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1194 | Genotropin 5.3 mg in injection system Genotropin pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1195 | Genotropin 5.3mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1196 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1197 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1198 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 💬 |
1199 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1200 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1201 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1202 | GENOTROPIN*1TBF 5,3MG (16UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 274 274 💬 |
1203 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 1件: Gentamicin
Gentamicin
💬 | - | - | 1件: 36 36 💬 |
1204 | GENZ-682452 | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 💬 |
1205 | Genz-682452-AA | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1206 | Genz-682452-AU | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 💬 |
1207 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 💬 |
1208 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1209 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1210 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1211 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1212 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
1213 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1214 | Ginkgo biloba pills sig: 300mg/tid | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 90 90 💬 |
1215 | Glatiramer Acetate (GA) 40 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1216 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1217 | Glatiramer acetate 40 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1218 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 💬 |
1219 | GLIVEC 400 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 💬 |
1220 | GLPG1690 600 mg QD | - | - | - | - | 1件: 85 85 💬 |
1221 | GLPG1837 dose 3 | - | - | - | - | 1件: 299 299 💬 |
1222 | GLPG2222 300 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
1223 | GLPG2222 400 mg | - | - | - | - | 1件: 299 299 💬 |
1224 | GLWL-01 | - | - | - | - | 1件: 193 193 💬 |
1225 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 13 13 💬 |
1226 | Glyceryl tri-(4-phenylbutyrate) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 251 251 💬 |
1227 | Glyceryl tri-(4-phenylbutyrate)(GT4P) | 2件: Glycerol phenylbutyrate Glycerol phenylbutyrate, Phenylbutyric acid | 1件: Glycerol phenylbutyrate
Glycerol phenylbutyrate
💬 | - | - | 1件: 251 251 💬 |
1228 | GNR-055 | - | - | - | - | 1件: 19 19 💬 |
1229 | GNR-055 1.0-2.0-3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1230 | GNR-055 2.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1231 | GNR-055 3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1232 | GNR-069 | - | - | - | - | 1件: 63 63 💬 |
1233 | Golimumab 4 mg per kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1234 | Golimumab 400 mg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1235 | GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) | 1件: Lenograstim Lenograstim | 1件: Lenograstim
Lenograstim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 💬 |
1236 | GRC 4039 | - | - | - | - | 1件: 46 46 💬 |
1237 | Group 3: ustekinumab approximately 6 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1238 | Growth hormone administration for 6 months | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1239 | Growth hormone releasing hormone (GHRH) 1-44 | 2件: Somatorelin Somatorelin, Somatotropin | 1件: Somatorelin
Somatorelin
💬 | 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 💬 |
1240 | GS-4059 | - | - | - | - | 1件: 53 53 💬 |
1241 | GS-4875 | - | - | - | - | 1件: 97 97 💬 |
1242 | GS-4997 18 mg | - | - | - | - | 1件: 86 86 💬 |
1243 | GS-4997 2 mg | - | - | - | - | 1件: 86 86 💬 |
1244 | GS-4997 6 mg | - | - | - | - | 1件: 86 86 💬 |
1245 | GS-6034 | - | - | - | - | 4件: 46 46, 53, 96, 97 💬 |
1246 | GS-6615 3 mg | - | - | - | - | 1件: 58 58 💬 |
1247 | GS-6615 3 mg Pink | - | - | - | - | 1件: 58 58 💬 |
1248 | GS-6615 3 mg White | - | - | - | - | 1件: 58 58 💬 |
1249 | GS-6615 6 mg | - | - | - | - | 1件: 58 58 💬 |
1250 | GS-6615 6 mg White | - | - | - | - | 1件: 58 58 💬 |
1251 | GS-6624 | 1件: Simtuzumab Simtuzumab | - | - | - | 2件: 85 85, 94 💬 |
1252 | GS-9411 | - | - | - | - | 1件: 299 299 💬 |
1253 | GS-9674 | - | - | - | - | 2件: 93 93, 94 💬 |
1254 | GS-9674 100 mg | - | - | - | - | 1件: 93 93 💬 |
1255 | GS-9674 30 mg | - | - | - | - | 1件: 93 93 💬 |
1256 | GS-9876 | - | - | - | - | 2件: 46 46, 53 💬 |
1257 | GSK 3196165 | - | - | - | - | 1件: 46 46 💬 |
1258 | GSK2330672/linerixibat 40 mg | - | - | - | - | 1件: 93 93 💬 |
1259 | GSK2402968 3mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1260 | GSK2402968 6 mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1261 | GSK2402968 6mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1262 | GSK2586184 400 mg | - | - | - | - | 1件: 49 49 💬 |
1263 | GSK2586184 400mg | - | - | - | - | 1件: 97 97 💬 |
1264 | GSK2982772 60 mg | - | - | - | - | 1件: 46 46 💬 |
1265 | GSK3196165 Dose 3 | - | - | - | - | 1件: 46 46 💬 |
1266 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
1267 | Guna-Interleukin 4 | - | - | - | - | 1件: 46 46 💬 |
1268 | Guselkumab Dose 3 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 💬 |
1269 | Guselkumab Dose 4 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1270 | GW-1000-02 | - | - | - | - | 1件: 13 13 💬 |
1271 | GX 623 | - | - | - | - | 1件: 135 135 💬 |
1272 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 💬 |
1273 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
1274 | H5.001CBCFTR | - | - | - | - | 1件: 299 299 💬 |
1275 | HBM9161 Injection (340 mg) | - | - | - | - | 1件: 11 11 💬 |
1276 | HBM9161 Injection (680mg and 340 mg) | - | - | - | - | 1件: 11 11 💬 |
1277 | HBM9161 Injection (680mg) | - | - | - | - | 1件: 11 11 💬 |
1278 | HBVAXPRO 5 micrograms/0.5 ml | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1279 | HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1280 | HBVAXPRO® 40 micrograms | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1281 | HEC 68498 | - | - | - | - | 1件: 85 85 💬 |
1282 | Helium-3 | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 2件: 228 228, 299 💬 |
1283 | Hemay007 600 mg QD group | - | - | - | - | 1件: 46 46 💬 |
1284 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
1285 | Hiomega-3 supplement of Naturalis® company - | - | - | - | - | 1件: 49 49 💬 |
1286 | HK-001 | - | - | - | - | 1件: 2 2 💬 |
1287 | HL-085 | - | - | - | - | 1件: 34 34 💬 |
1288 | HLADQA1*05A>G screening | - | - | - | - | 2件: 96 96, 97 💬 |
1289 | HLB-001 | - | - | - | - | 1件: 246 246 💬 |
1290 | HMPL-004 | - | - | - | - | 2件: 96 96, 97 💬 |
1291 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
1292 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
1293 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
1294 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
1295 | HMPL-523(300mg PO QD) | - | - | - | - | 1件: 61 61 💬 |
1296 | HMPL004-6599 | - | - | - | - | 2件: 96 96, 97 💬 |
1297 | HP 3He | - | - | - | - | 1件: 299 299 💬 |
1298 | HP-3000 (ropinirole hydrochloride patch) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1299 | HP-3000 placebo | - | - | - | - | 1件: 6 6 💬 |
1300 | HP-3000(ropinirole hydrochloride patch) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1301 | Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40 | - | - | - | - | 1件: 96 96 💬 |
1302 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 💬 |
1303 | Humanized anti-alpha v beta 6 mAb | - | - | - | - | 1件: 85 85 💬 |
1304 | Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
1305 | Humatrope® 6 mg, powder and solvent for solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1306 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 💬 |
1307 | Humira (adalimumab) 40 mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1308 | Humira (adalimumab) 40 mg s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1309 | Humira (adalimumab) 40mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1310 | Humira (adalimumab) 40mg in 0.4ml s.c.injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1311 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
1312 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1313 | HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1314 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1315 | Humira 40 mg injekcní roztok v predplnené injekcní stríkacce | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1316 | Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte | - | - | - | - | 1件: 46 46 💬 |
1317 | HUMIRA 40 mg solución inyectable en jeringa precargada | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1318 | Humira 40 mg solution for injection in pre-filled pen | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1319 | Humira 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 97 💬 |
1320 | Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1321 | Humira 40 mg solution for injection in pre-filled syringes | - | - | - | - | 1件: 97 97 💬 |
1322 | Humira 40 mg/0.8 ml solution for injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
1323 | Humira 40 mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1324 | Humira 40mg Injektionslösung | - | - | - | - | 1件: 46 46 💬 |
1325 | HUMIRA 40Mg Solution for Injection | - | - | - | - | 2件: 96 96, 97 💬 |
1326 | Humira 40mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1327 | Humira 40mg solution for injection in pre-filled syringe (adalimumab) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1328 | Humira 40mg/0.4ml pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1329 | Humira 40mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1330 | Humira 40mg/0.8ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1331 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1332 | Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1333 | Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1334 | HUMIRA*SC 2SIR+F 40MG 0,8ML+2T | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1335 | Humira, 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1336 | Humira® 40 mg Injektionslösung in Fertigspritze | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1337 | Humira® 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1338 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1339 | Hydroxychloroquine 400mg/d | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 53 53 💬 |
1340 | Hyperpolarized Helium-3 | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 299 299 💬 |
1341 | Hyperpolarized Helium-3 MRI | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 228 228 💬 |
1342 | Hyperpolarized Helium-3 MRI of the chest | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 299 299 💬 |
1343 | Hypertonic saline (7 %) and isotonic saline (0.9%) | - | - | - | - | 1件: 299 299 💬 |
1344 | Hypertonic saline 6% - | - | - | - | - | 1件: 299 299 💬 |
1345 | Ibuprofen Sandoz 400 mg Filmtabletten | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1346 | ICP-022 | - | - | - | - | 2件: 46 46, 49 💬 |
1347 | ICX-RHY-013 | - | - | - | - | 1件: 36 36 💬 |
1348 | IDEC-C2B8, Ro 45-2294 | - | - | - | - | 1件: 64 64 💬 |
1349 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
1350 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
1351 | IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G | - | - | - | - | 1件: 272 272 💬 |
1352 | Idursulfase IT (30 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1353 | IFB-088 | - | - | - | - | 1件: 2 2 💬 |
1354 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
1355 | IFN beta 1a 44 mcg TIW | - | - | - | - | 1件: 13 13 💬 |
1356 | IgG2/4? | - | - | - | - | 1件: 109 109 💬 |
1357 | IL-6 receptor inhibitor, humanized monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
1358 | IL-6 receptor inhibitor, recombinant humanized monoclonal antibody | - | - | - | - | 2件: 46 46, 107 💬 |
1359 | IL-6R Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 46 46 💬 |
1360 | IL-6R Monoclonal Antibody Injection 6mg/kg | - | - | - | - | 1件: 46 46 💬 |
1361 | IL-6R Monoclonal Antibody Injection 8mg/kg | - | - | - | - | 1件: 46 46 💬 |
1362 | IL-6R nanobody | - | - | - | - | 1件: 49 49 💬 |
1363 | Iloprost (Ventavis, BAYQ 6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1364 | Iloprost PD-6 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1365 | ILV-094 | - | - | - | - | 1件: 46 46 💬 |
1366 | Imatinib Mesylate 400Mg Capsule | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 89 89 💬 |
1367 | IMCY-0141 | 1件: IMCY-0141 IMCY-0141 | - | - | - | 1件: 13 13 💬 |
1368 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
1369 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | 1件: 96 96 💬 |
1370 | IMU-838 (30 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1371 | IMU-838 (45 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1372 | IMUKIN - 6 FLACONI 0.5 ML 100 MCG | - | - | - | - | 2件: 18 18, 58 💬 |
1373 | IMUKIN*SC 6F 0,5ML 100MCG | - | - | - | - | 1件: 18 18 💬 |
1374 | Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus | - | - | - | - | 1件: 53 53 💬 |
1375 | INCB050465 0.3 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1376 | INCB050465 0.3mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1377 | INCB050465 1.0 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1378 | INCB050465 1.0mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1379 | INCRELEX*SC 1FL 4ML 10MG/ML | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1380 | INDUSIL*OS GTT FL 30MG+FL 15ML | - | - | - | - | 1件: 299 299 💬 |
1381 | Infigratinib 0.016 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1382 | Infigratinib 0.032 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1383 | Infigratinib 0.064 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1384 | Infigratinib 0.128 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1385 | Infigratinib 0.25 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1386 | Infliximab (BCD-055) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1387 | Infliximab 3 mg/kg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1388 | Infliximab 5 mg/kg every 6 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1389 | Infliximab [infliximab biosimilar 3] | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 37 37, 46, 96, 97 💬 |
1390 | Infliximab and azathioprine combination at week 0 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1391 | Infusion of ADR-001 (Mesenchymal stem cell) | - | - | - | - | 1件: 66 66 💬 |
1392 | Inhaled Nitric Oxide - 30 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1393 | INOmax 400ppm mol/mol inhalation gas | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 299 💬 |
1394 | INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE | 1件: Etravirine Etravirine | 1件: Etravirine
Etravirine
💬 | - | - | 1件: 18 18 💬 |
1395 | Interferon beta 1a 30 ug IM once weekly | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1396 | Interferon beta-1a 30 µg | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1397 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1398 | Interferon beta-1b, FRP about 6 weeks after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1399 | Interferon ß-1a 30 µg | - | - | - | - | 1件: 13 13 💬 |
1400 | Interferon-beta-1a, 44 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
1401 | Interferon-beta-1a, 66 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
1402 | Interleukin 4 | - | - | - | - | 1件: 46 46 💬 |
1403 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1404 | Intravenous administration of 4 million of MSC | - | - | - | - | 1件: 2 2 💬 |
1405 | Iohexol Inj 300 milligrams per milliliter (MG/ML) | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 67 67 💬 |
1406 | ION-682884 | - | - | - | - | 1件: 28 28 💬 |
1407 | IPX054 300 mg | - | - | - | - | 1件: 6 6 💬 |
1408 | IPX056 30 mg | - | - | - | - | 1件: 13 13 💬 |
1409 | IPX056 35 mg | - | - | - | - | 1件: 13 13 💬 |
1410 | IPX056 40 mg | - | - | - | - | 1件: 13 13 💬 |
1411 | IPX056-30 mg | - | - | - | - | 1件: 13 13 💬 |
1412 | IPX056-35 mg | - | - | - | - | 1件: 13 13 💬 |
1413 | IPX056-40 mg | - | - | - | - | 1件: 13 13 💬 |
1414 | IPX066 95 mg | - | - | - | - | 1件: 6 6 💬 |
1415 | IPX066 95 mg LD | - | - | - | - | 1件: 6 6 💬 |
1416 | IPX066-95 | - | - | - | - | 1件: 6 6 💬 |
1417 | IPX203 350 mg | - | - | - | - | 1件: 6 6 💬 |
1418 | IRAK 4 | - | - | - | - | 1件: 46 46 💬 |
1419 | Irbesartan 150-300mg capsules daily for 6 months | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1420 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
1421 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
1422 | Irbesartan tablets (NDC# 31722-729-30 approved in the United states) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1423 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1424 | Iron supplement 300-600 mg/day | 1件: Iron Iron | - | - | - | 2件: 96 96, 97 💬 |
1425 | ISIS 301012 | - | - | - | - | 1件: 79 79 💬 |
1426 | ISIS 301012 phosphorothioate oligonucleotide | - | - | - | - | 1件: 79 79 💬 |
1427 | ISIS 304801 | - | - | - | - | 1件: 265 265 💬 |
1428 | ISIS 333611 | - | - | - | - | 1件: 2 2 💬 |
1429 | ISIS 396443 | - | - | - | - | 1件: 3 3 💬 |
1430 | ISIS 396443 (BIIB058) | - | - | - | - | 1件: 3 3 💬 |
1431 | ISIS 396443, BIIB058 | - | - | - | - | 1件: 3 3 💬 |
1432 | ISIS 420915 | - | - | - | - | 1件: 28 28 💬 |
1433 | Isis 420915/GSK 299872 | - | - | - | - | 1件: 28 28 💬 |
1434 | ISIS 443139 10 mg | - | - | - | - | 1件: 8 8 💬 |
1435 | ISIS 443139 120 mg | - | - | - | - | 1件: 8 8 💬 |
1436 | ISIS 443139 30 mg | - | - | - | - | 1件: 8 8 💬 |
1437 | ISIS 443139 60 mg | - | - | - | - | 1件: 8 8 💬 |
1438 | ISIS 443139 90 mg | - | - | - | - | 1件: 8 8 💬 |
1439 | Isosorbide Dinitrate 40 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1440 | Isosorbide Dinitrate 60 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1441 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 💬 |
1442 | Isotonic saline 0.9% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1443 | Istradefylline ( KW-6002) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1444 | Istradefylline (KW-6002) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1445 | Istradefylline 20 mg or 40 mg | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1446 | Istradefylline 40 mg | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1447 | Itolizumab [Bmab 600] | 1件: Itolizumab Itolizumab | 1件: Itolizumab
Itolizumab
💬 | 1件: CD6 CD6 💬 | 1件: Cell adhesion molecules Cell adhesion molecules 💬 | 1件: 49 49 💬 |
1448 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. | 2件: Itraconazole Itraconazole, Terbinafine | 2件: Itraconazole
Itraconazole
,
Terbinafine
💬 | - | - | 1件: 96 96 💬 |
1449 | IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
1450 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
1451 | IVA 336 | - | - | - | - | 1件: 19 19 💬 |
1452 | IW-3300 rectal foam | - | - | - | - | 1件: 226 226 💬 |
1453 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬 |
1454 | JAK 3 | - | - | - | - | 1件: 46 46 💬 |
1455 | JAK 3 Ritlecitinib | - | - | - | - | 1件: 46 46 💬 |
1456 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬 |
1457 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1458 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1459 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1460 | JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1461 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1462 | Jinarc 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1463 | Jinarc 30 mg tablets, 90 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1464 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1465 | Jinarc® 30 Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1466 | JM-010 | - | - | - | - | 1件: 6 6 💬 |
1467 | JM-4 | - | - | - | - | 1件: 13 13 💬 |
1468 | JNJ 38518168 | - | - | - | - | 1件: 46 46 💬 |
1469 | JNJ-31001074 | - | - | - | - | 1件: 6 6 💬 |
1470 | JNJ-38518168 | - | - | - | - | 1件: 46 46 💬 |
1471 | JNJ-38518168 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
1472 | JNJ-38518168 (3 mg) | - | - | - | - | 1件: 46 46 💬 |
1473 | JNJ-38518168 (30 mg) | - | - | - | - | 1件: 46 46 💬 |
1474 | JNJ-38518168 / MTX | - | - | - | - | 1件: 46 46 💬 |
1475 | JNJ-38518168 50-mg Over Encapsulated Tablet | - | - | - | - | 1件: 46 46 💬 |
1476 | JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg | - | - | - | - | 1件: 46 46 💬 |
1477 | JNJ-38518168-ZBQ | - | - | - | - | 1件: 46 46 💬 |
1478 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
1479 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 💬 |
1480 | JNJ-38518168-ZBQ - film-coated tablet - 3 mg | - | - | - | - | 1件: 46 46 💬 |
1481 | JNJ-38518168-ZBQ - film-coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬 |
1482 | JNJ-38518168-ZBQ - film-coated tablet - 30mg | - | - | - | - | 1件: 46 46 💬 |
1483 | JNJ-38518168-ZBQ - film-coated tablet - 3mg | - | - | - | - | 1件: 46 46 💬 |
1484 | JNJ-39039039 | - | - | - | - | 1件: 210 210 💬 |
1485 | JNJ-39758979 | - | - | - | - | 1件: 46 46 💬 |
1486 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
1487 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 💬 |
1488 | JNJ-39758979 (30 mg) | - | - | - | - | 1件: 46 46 💬 |
1489 | JNJ-39758979 (300 mg) | - | - | - | - | 1件: 46 46 💬 |
1490 | JNJ-39758979 / MTX | - | - | - | - | 1件: 46 46 💬 |
1491 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
1492 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 💬 |
1493 | JNJ-39758979-AAC - enteric coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬 |
1494 | JNJ-40346527 | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 2件: 46 46, 96 💬 |
1495 | JNJ-40346527-AAC | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
1496 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 💬 |
1497 | JNJ-42160443 | - | - | - | - | 1件: 226 226 💬 |
1498 | JNJ-54781532-AAD-30 mg | - | - | - | - | 1件: 97 97 💬 |
1499 | JNJ-64304500 | - | - | - | - | 1件: 96 96 💬 |
1500 | JNJ-64304500-AAA | - | - | - | - | 1件: 96 96 💬 |
1501 | JNJ-64841829 | - | - | - | - | 1件: 97 97 💬 |
1502 | JNJ-64841842 | - | - | - | - | 1件: 97 97 💬 |
1503 | JNJ-64841855 | - | - | - | - | 1件: 97 97 💬 |
1504 | JNJ-64841894 | - | - | - | - | 1件: 97 97 💬 |
1505 | JNJ-64841907 | - | - | - | - | 1件: 97 97 💬 |
1506 | JNJ-64841920 | - | - | - | - | 1件: 97 97 💬 |
1507 | JNJ-64841933 | - | - | - | - | 1件: 97 97 💬 |
1508 | JNJ-64841946 | - | - | - | - | 1件: 97 97 💬 |
1509 | JNJ-66525433 | - | - | - | - | 1件: 97 97 💬 |
1510 | JNJ-67484703 | - | - | - | - | 1件: 46 46 💬 |
1511 | JNJ-67864238 | - | - | - | - | 1件: 96 96 💬 |
1512 | JNJ-67896049 | - | - | - | - | 1件: 86 86 💬 |
1513 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 💬 |
1514 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
1515 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
1516 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
1517 | JNJ-67896153/ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
1518 | JNJ31-31001074 | - | - | - | - | 1件: 6 6 💬 |
1519 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1520 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1521 | JTE-051 | - | - | - | - | 1件: 46 46 💬 |
1522 | Kamillenblüten 3ml/10ml | - | - | - | - | 1件: 97 97 💬 |
1523 | KCT-0809 ophthalmic solution | - | - | - | - | 1件: 53 53 💬 |
1524 | KDT-3594 | 1件: KDT-3594 KDT-3594 | - | - | - | 1件: 6 6 💬 |
1525 | Ketocal 4:1 liquid Nutricia (intervention) | - | - | - | - | 1件: 256 256 💬 |
1526 | KINERET*SC 7SIR 100MG 0,67ML | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 28 28, 46, 107 💬 |
1527 | KIO-301 | - | - | - | - | 1件: 90 90 💬 |
1528 | KPL-301 | - | - | - | - | 1件: 41 41 💬 |
1529 | KPL-404 | - | - | - | - | 1件: 46 46 💬 |
1530 | KPS-0373 | - | - | - | - | 1件: 18 18 💬 |
1531 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
1532 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
1533 | Kreon 25 000 | - | - | - | - | 1件: 299 299 💬 |
1534 | Kreon 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1535 | Kreon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1536 | KVD824 300 mg Compresse a rilascio modificato | - | - | - | - | 1件: 65 65 💬 |
1537 | KVD824 300 mg Modified Release Tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 65 65 💬 |
1538 | KVD900 300 mg | - | - | - | - | 1件: 65 65 💬 |
1539 | KVD900 300 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
1540 | KVD900 600 mg | - | - | - | - | 1件: 65 65 💬 |
1541 | KW-0761 | - | - | - | - | 1件: 26 26 💬 |
1542 | KW-0761 0.3 mg/kg IV | - | - | - | - | 1件: 26 26 💬 |
1543 | KW-6002 | - | - | - | - | 1件: 6 6 💬 |
1544 | KW-6002 (istradefylline) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1545 | KW-6356 | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1546 | KW-6356 High Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1547 | KW-6356 Low Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1548 | KW-6356 Middle Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1549 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1550 | KW-6356 Y Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1551 | KW-6500 | - | - | - | - | 1件: 6 6 💬 |
1552 | KZR-616 | 1件: KZR-616 KZR-616 | - | - | - | 3件: 49 49, 50, 61 💬 |
1553 | KZR-616 maleate | 1件: KZR-616 KZR-616 | - | - | - | 1件: 50 50 💬 |
1554 | L 44 | - | - | - | - | 1件: 96 96 💬 |
1555 | L-000124467 | - | - | - | - | 2件: 13 13, 46 💬 |
1556 | L-000124467 (freebase) | - | - | - | - | 1件: 46 46 💬 |
1557 | L-000124467-009J (succinat | - | - | - | - | 1件: 46 46 💬 |
1558 | L-000883191 | - | - | - | - | 1件: 46 46 💬 |
1559 | L-001069957 | - | - | - | - | 1件: 46 46 💬 |
1560 | L-3-(3,4-Dihydroxyphenyl)alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
1561 | L03 AB 08 | - | - | - | - | 1件: 13 13 💬 |
1562 | Lansoprazole 30mg | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 166 166 💬 |
1563 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1564 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1565 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1566 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1567 | Laquinimod capsules 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 2件: 8 8, 96 💬 |
1568 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1569 | Laquinimod Cápsulas 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 96 96 💬 |
1570 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1571 | LC51-0255 | - | - | - | - | 1件: 97 97 💬 |
1572 | LDP-02 | - | - | - | - | 2件: 96 96, 97 💬 |
1573 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
1574 | Leuprolide Acetate 3 Month Depot | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1575 | Leuprolide acetate 30 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1576 | Leuprolide Acetate 45 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1577 | Leuprorelin Acetate 3.75mg Injection | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1578 | Leuprorelin Acetate Depot 3M | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1579 | Levodopa-4'-Monophosphate | 2件: Foslevodopa Foslevodopa, Levodopa | 2件: Levodopa
Levodopa
,
Foslevodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1580 | Levodopa/Carbidopa (4:1) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 201 201 💬 |
1581 | LEVOFOLENE 4 MG 30 CPR | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 💬 |
1582 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1583 | Linerixibat (GSK2330672) 40 mg | - | - | - | - | 1件: 93 93 💬 |
1584 | Linerixibat (GSK2330672) 45 mg | - | - | - | - | 1件: 93 93 💬 |
1585 | Linerixibat (GSK2330672) 45mg | - | - | - | - | 1件: 93 93 💬 |
1586 | Lipoic acid and omega-3 fatty acids | 2件: Lipoic acid Lipoic acid, Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
1587 | LiRIS 400 mg | - | - | - | - | 1件: 226 226 💬 |
1588 | LiRIS® 400 mg | - | - | - | - | 1件: 226 226 💬 |
1589 | Lithiumcarbonaat 400 PCH tabletten | - | - | - | - | 1件: 2 2 💬 |
1590 | LJN452, 0,01 mg | - | - | - | - | 1件: 93 93 💬 |
1591 | LJN452, 0,03 mg | - | - | - | - | 1件: 93 93 💬 |
1592 | LJN452, 0,1 mg | - | - | - | - | 1件: 93 93 💬 |
1593 | LJP 394 | - | - | - | - | 1件: 49 49 💬 |
1594 | LMX 4 Topical Cream | - | - | - | - | 1件: 256 256 💬 |
1595 | Local Trade Name, 4mg | - | - | - | - | 1件: 6 6 💬 |
1596 | Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
1597 | Long-chain n-3 PUFA | - | - | - | - | 1件: 46 46 💬 |
1598 | Lovastatin 60 MG | 1件: Lovastatin Lovastatin | 1件: Lovastatin
Lovastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 34 34 💬 |
1599 | Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
1600 | LP-08 20mg | - | - | - | - | 1件: 226 226 💬 |
1601 | LP-08 80mg | - | - | - | - | 1件: 226 226 💬 |
1602 | LT-02 | - | - | - | - | 1件: 97 97 💬 |
1603 | LT-02 (modified-release PC pellets) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
1604 | LTS 0.25mg | - | - | - | - | 1件: 46 46 💬 |
1605 | LTS 0.5mg | - | - | - | - | 1件: 46 46 💬 |
1606 | LTS 1.0mg | - | - | - | - | 1件: 46 46 💬 |
1607 | Lu 00-800 | - | - | - | - | 1件: 6 6 💬 |
1608 | Lumentin 44 | - | - | - | - | 1件: 96 96 💬 |
1609 | Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1610 | Lutein (10 or 30 mg/day) capsules | 1件: Lutein Lutein | - | - | - | 1件: 90 90 💬 |
1611 | LYC-30937 | - | - | - | - | 1件: 97 97 💬 |
1612 | LYC-30937-EC | - | - | - | - | 1件: 97 97 💬 |
1613 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1614 | Macitentan 3 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1615 | Macitentan 37.5 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1616 | Macitentan 3mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1617 | Macrogol 4000 | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 299 299 💬 |
1618 | Masitinib (3.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1619 | Masitinib (4.5) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 13 💬 |
1620 | Masitinib (6.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1621 | Masitinib 3 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
1622 | Masitinib 6.0 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
1623 | MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
1624 | Mavrilimumab 30 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
1625 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1626 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1627 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
1628 | MBS2320 40 mg | - | - | - | - | 1件: 46 46 💬 |
1629 | MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | - | - | - | - | 1件: 79 79 💬 |
1630 | MD-0901 | - | - | - | - | 1件: 97 97 💬 |
1631 | MDGN-002 | - | - | - | - | 1件: 96 96 💬 |
1632 | MEDI-545 600 | - | - | - | - | 1件: 49 49 💬 |
1633 | MEDI-551 30 MG-IV | - | - | - | - | 1件: 13 13 💬 |
1634 | MEDI-551 300 MG-SC | - | - | - | - | 1件: 13 13 💬 |
1635 | MEDI-551 60 MG-SC | - | - | - | - | 1件: 13 13 💬 |
1636 | MEDI-551 600 MG-IV | - | - | - | - | 1件: 13 13 💬 |
1637 | MEDI-570 0.03 MG | - | - | - | - | 1件: 49 49 💬 |
1638 | MEDI-570 0.1 MG | - | - | - | - | 1件: 49 49 💬 |
1639 | MEDI-570 0.3 MG | - | - | - | - | 1件: 49 49 💬 |
1640 | MEDROL - 4 MG COMPRESSE 30 COMPRESSE | - | - | - | - | 1件: 56 56 💬 |
1641 | Medrol 4 mg tablets | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1642 | MEDROL*10CPR DIV 4MG | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1643 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1644 | Meloxicam 0.125 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1645 | Meloxicam 0.25 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1646 | Mepolizumab 300 mg | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
1647 | Mesalamine Delayed Release Tablets 400mg | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1648 | Mesalazine (3,600 mg) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1649 | Mesalazine 4G Enema | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1650 | Mesenchymal stem cell 0.5 | - | - | - | - | 1件: 228 228 💬 |
1651 | Mesenchymal stem cell 1.0 | - | - | - | - | 1件: 228 228 💬 |
1652 | Metalcaptase® 300 mg gastro-resistant tablet | - | - | - | - | 1件: 171 171 💬 |
1653 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
1654 | Metformin/CP-690,550 | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1655 | METFORMINA - 500 30 COMPRESSE 500 MG | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
1656 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
1657 | Methotrexate plus ERB-041 for 12 weeks | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1658 | METHOTREXATE*10MG/1,33ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1659 | METHOTREXATE*15MG/2ML 4SIR | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1660 | METHOTREXATE*20MG/2,66ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1661 | METHOTREXATE*7,5MG/ML 4SIR. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1662 | Methotrexate, Leucovorin and BMS-986142 | 3件: BMS-986142 BMS-986142, Leucovorin, Methotrexate | 3件: Methotrexate
Methotrexate
,
Folinic acid
,
Folinic acid calcium salt pentahydrate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1663 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1664 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1665 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo | - | - | - | - | 1件: 86 86 💬 |
1666 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 💬 |
1667 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 💬 |
1668 | Methylphenidate modified release 30 mg | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1669 | Methylphenidate modified release 40 mg | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1670 | Methylprednisolone bolus IV 15 mg/kg/d for 3 days. | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1671 | Methylprednisolone(intravenously in the 1st-2nd-3rd month ) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1672 | Methylprednisolone(intravenously in the 1st-3rd-5th month) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1673 | MetoHEXAL® Succ ® 47,5 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
1674 | MetoHEXAL® Succ ® 95 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
1675 | MH004 Ia(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1676 | MH004 Ia(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1677 | MH004 Ia(3%) | - | - | - | - | 1件: 46 46 💬 |
1678 | MH004 Ib-1(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1679 | MH004 Ib-1(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1680 | MH004 Ib-2(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1681 | MH004 Ib-2(3%) | - | - | - | - | 1件: 46 46 💬 |
1682 | MIB-626 | - | - | - | - | 1件: 18 18 💬 |
1683 | Microgynon® 30 (Oral contraceptive) | - | - | - | - | 1件: 46 46 💬 |
1684 | Midazolam 3 mg | 1件: Midazolam Midazolam | 1件: Midazolam
Midazolam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 96 96 💬 |
1685 | MIRAPEXIN*30CPR 0,7MG | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1686 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1687 | MK-0653 | - | - | - | - | 1件: 260 260 💬 |
1688 | MK-0663 | - | - | - | - | 2件: 46 46, 271 💬 |
1689 | MK-0859 | - | - | - | - | 1件: 79 79 💬 |
1690 | MK-0873 | 1件: MK-0873 MK-0873 | - | - | - | 1件: 46 46 💬 |
1691 | MK-3222 | - | - | - | - | 1件: 271 271 💬 |
1692 | MK-4836 | - | - | - | - | 2件: 86 86, 88 💬 |
1693 | MK-6194 | - | - | - | - | 1件: 97 97 💬 |
1694 | MM-093 | 1件: MM-093 MM-093 | - | - | - | 1件: 46 46 💬 |
1695 | MN-001 | - | - | - | - | 1件: 226 226 💬 |
1696 | MN-001 BID | - | - | - | - | 1件: 226 226 💬 |
1697 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
1698 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
1699 | MOD-4023 | - | - | - | - | 1件: 78 78 💬 |
1700 | Modified Oral Glucose Tolerance Test (50g 4-hours) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 💬 |
1701 | Modopar 62,5 | - | - | - | - | 1件: 6 6 💬 |
1702 | Molgramostim 300 mcg nebuliser solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1703 | Molgramostim 300 µg nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1704 | Molgramostim Nebuliser solution 300 mcg | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1705 | MONORES*30CPR 20MCG | - | - | - | - | 1件: 1 1 💬 |
1706 | Monotherapy (Lopinavir/ritonavir) + ABC/3TC | 2件: Lopinavir Lopinavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
1707 | Monovalent [B.1.351] CoV2 preS dTM-AS03 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
1708 | Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142 | 6件: BMS-986142 BMS-986142, Digoxin, Flurbiprofen, Midazolam, Montelukast, Pravastatin | 5件: Digoxin
Digoxin
,
Flurbiprofen
,
Midazolam
,
Montelukast
,
Pravastatin
💬 | 24件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HMGCR, PTGS1, PTGS2 💬 | 49件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Terpenoid backbone biosynthesis, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1709 | Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
1710 | MORAb-022 | - | - | - | - | 1件: 46 46 💬 |
1711 | MORF-057 | - | - | - | - | 1件: 97 97 💬 |
1712 | Moxifloxacin 400 mg | 1件: Moxifloxacin Moxifloxacin | 1件: Moxifloxacin
Moxifloxacin
💬 | - | - | 1件: 86 86 💬 |
1713 | MP-376 | - | - | - | - | 1件: 299 299 💬 |
1714 | MP-376 (Levofloxacin Solution for Inhalation) | 1件: Levofloxacin Levofloxacin | 2件: Levofloxacin
Levofloxacin
,
Levofloxacin
💬 | - | - | 1件: 299 299 💬 |
1715 | MP-435(dose1) + Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1716 | MR-MC-01 | - | - | - | - | 1件: 226 226 💬 |
1717 | MRA 003 US | - | - | - | - | 1件: 49 49 💬 |
1718 | MRNA-3704 | - | - | - | - | 1件: 246 246 💬 |
1719 | MRNA-3705 | - | - | - | - | 1件: 246 246 💬 |
1720 | MRNA-3927 | - | - | - | - | 1件: 245 245 💬 |
1721 | MSC injection 01 | - | - | - | - | 1件: 96 96 💬 |
1722 | MSC injection 02 | - | - | - | - | 1件: 96 96 💬 |
1723 | MSC treatment 01 | - | - | - | - | 1件: 96 96 💬 |
1724 | MSC treatment 02 | - | - | - | - | 1件: 96 96 💬 |
1725 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 💬 |
1726 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 💬 |
1727 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 💬 |
1728 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 💬 |
1729 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 💬 |
1730 | MT-3921 | - | - | - | - | 1件: 26 26 💬 |
1731 | MTC TRx0014-001 capsules | - | - | - | - | 1件: 127 127 💬 |
1732 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
1733 | Mycophenolate Mofetil (MMF) 3 g/Day | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 35 35 💬 |
1734 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 💬 |
1735 | MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion | - | - | - | - | 1件: 65 65 💬 |
1736 | MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion | - | - | - | - | 1件: 65 65 💬 |
1737 | MYELOSTIM 34*1FL 263MCG+1SIR | - | - | - | - | 1件: 2 2 💬 |
1738 | Myfortic 360mg Tablets | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 66 66, 222 💬 |
1739 | MYFORTIC*50CPR RIV 360MG | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 49 49 💬 |
1740 | MYK-461 | - | - | - | - | 1件: 58 58 💬 |
1741 | MYO-029 | 1件: Stamulumab Stamulumab | 1件: Stamulumab
Stamulumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
1742 | MYONAL*30CPR RIV 100MG | - | - | - | - | 1件: 2 2 💬 |
1743 | N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
1744 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1745 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1746 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1747 | N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
1748 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1749 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1750 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 💬 |
1751 | N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1752 | N-0923 | - | - | - | - | 1件: 6 6 💬 |
1753 | N-3 LC-PUFA | - | - | - | - | 1件: 46 46 💬 |
1754 | N-3 Polyunsaturated Fatty Acids | - | - | - | - | 1件: 96 96 💬 |
1755 | N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide | 2件: Acetamide Acetamide, Pyrazole | - | - | - | 1件: 154 154 💬 |
1756 | N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
1757 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 💬 |
1758 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 💬 |
1759 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | - | - | - | 1件: 265 265 💬 |
1760 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium | - | - | - | - | 1件: 96 96 💬 |
1761 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium | - | - | - | - | 1件: 96 96 💬 |
1762 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
1763 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 💬 |
1764 | NaCl 0.9% | - | - | - | - | 1件: 39 39 💬 |
1765 | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1766 | Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1767 | Natalizumab 300 MG in 15 ML Injection | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1768 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
1769 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 288 288 💬 |
1770 | Natriumklorid 9mg/ml | - | - | - | - | 1件: 46 46 💬 |
1771 | NBT-NM108 (60 g/day) | - | - | - | - | 1件: 13 13 💬 |
1772 | NBTX-001 | - | - | - | - | 1件: 6 6 💬 |
1773 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 💬 |
1774 | NDV-3A | - | - | - | - | 1件: 65 65 💬 |
1775 | NEB/01-07 | - | - | - | - | 1件: 299 299 💬 |
1776 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: Testosterone
Testosterone
,
Testosterone undecanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
1777 | NEUPRO 4 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1778 | Neupro 4 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1779 | Neupro 4mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1780 | Neupro 4mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1781 | Neupro 4Mg/24Hr Transdermal Patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1782 | NEUPRO 6 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1783 | Neupro 6 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1784 | Neupro 6mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1785 | Neupro 6mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1786 | NEUPRO*28CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1787 | NEUPRO*28CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1788 | NEUPRO*7CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1789 | NEUPRO*7CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1790 | Neurontin 300 mg hard capsule | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1791 | NeuroVax 300ug/mL Dose for IM Injection | 1件: NeuroVax NeuroVax | - | - | - | 1件: 13 13 💬 |
1792 | Nexavar (BAY 43-9006) (Sorafenib) | 1件: Sorafenib Sorafenib | 1件: Sorafenib
Sorafenib
💬 | 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1793 | NI-0101 | - | - | - | - | 1件: 46 46 💬 |
1794 | NI-03 | - | - | - | - | 1件: 298 298 💬 |
1795 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 💬 |
1796 | NI-0501 | - | - | - | - | 1件: 107 107 💬 |
1797 | NI-071 | - | - | - | - | 1件: 46 46 💬 |
1798 | NI-0801 | - | - | - | - | 1件: 93 93 💬 |
1799 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
1800 | Nicotinell 35 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 💬 |
1801 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1802 | Nilotinib 300mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
1803 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 💬 |
1804 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 💬 |
1805 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 💬 |
1806 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 💬 |
1807 | NNC 126-0083 | - | - | - | - | 1件: 78 78 💬 |
1808 | NNC 142-0002 | - | - | - | - | 1件: 46 46 💬 |
1809 | NNC0109-0012 | - | - | - | - | 1件: 46 46 💬 |
1810 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 💬 |
1811 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 💬 |
1812 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 💬 |
1813 | NNC0142-0002 | - | - | - | - | 1件: 46 46 💬 |
1814 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 💬 |
1815 | NNC0195-0092 | - | - | - | - | 1件: 78 78 💬 |
1816 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1817 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 💬 |
1818 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1819 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
1820 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1821 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1822 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 💬 |
1823 | NNC109-0012 | - | - | - | - | 1件: 46 46 💬 |
1824 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 💬 |
1825 | NNC142-0002 | - | - | - | - | 1件: 96 96 💬 |
1826 | NNC151-0000 | - | - | - | - | 1件: 46 46 💬 |
1827 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 💬 |
1828 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 💬 |
1829 | NOXAFIL - 40 mg/ml oral suspension | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1830 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1831 | NOXAFIL - oral suspension 40 mg/ml | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1832 | Noxafil 40 mg/ml oral solution | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 65 65 💬 |
1833 | NP031112 600mg | - | - | - | - | 1件: 5 5 💬 |
1834 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 💬 |
1835 | NPC-02 | - | - | - | - | 1件: 171 171 💬 |
1836 | NPC-09 | - | - | - | - | 1件: 30 30 💬 |
1837 | NPI-001 | - | - | - | - | 2件: 90 90, 303 💬 |
1838 | NR2B NMDA Antagonist CP-101,606 (traxoprodil) | 1件: Ketamine Ketamine | 1件: Ketamine
Ketamine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1839 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
1840 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
1841 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 💬 |
1842 | NS-304 Placebo | - | - | - | - | 2件: 70 70, 88 💬 |
1843 | NT-KO-003 | - | - | - | - | 1件: 13 13 💬 |
1844 | NutropinAq 10 mg/2 ml (30 UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1845 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1846 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | - | - | - | 1件: 65 65 💬 |
1847 | NYX-458 | - | - | - | - | 1件: 6 6 💬 |
1848 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 💬 |
1849 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 💬 |
1850 | OCA 0.1mg | - | - | - | - | 1件: 296 296 💬 |
1851 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1852 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1853 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1854 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1855 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1856 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1857 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1858 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1859 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 💬 |
1860 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
1861 | ODM-101 65mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1862 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1863 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1864 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1865 | Ofatumumab 300 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1866 | Ofatumumab 30mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1867 | Ofatumumab 3mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1868 | Ofatumumab 60mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1869 | OGT 918 | - | - | - | - | 2件: 19 19, 299 💬 |
1870 | Okrido 6mg/mL oral solution | - | - | - | - | 1件: 3 3 💬 |
1871 | OL adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1872 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 💬 |
1873 | OligoG (60 mg/ml) | - | - | - | - | 1件: 299 299 💬 |
1874 | OligoG CF/20 - 37.5 mg | - | - | - | - | 1件: 299 299 💬 |
1875 | OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
1876 | Oligomero morfolino fosforodiamidato per skipping dell’esone 45 | - | - | - | - | 1件: 113 113 💬 |
1877 | Olokizumab 60 mg | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1878 | Olokizumab 64 mg SC q2w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1879 | Olokizumab 64 mg SC q4w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1880 | Olokizumab 64mg q2w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1881 | Olokizumab 64mg q4w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1882 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1883 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1884 | OLUMIANT 4 mg | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1885 | OLUMIANT 4mg | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1886 | Omaveloxolone Capsules, 300 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1887 | Omaveloxolone Capsules, 40 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1888 | Omega 3 | - | - | - | - | 3件: 13 13, 53, 299 💬 |
1889 | Omega 3 fatty acid | - | - | - | - | 1件: 53 53 💬 |
1890 | Omega 3 Premium | - | - | - | - | 1件: 299 299 💬 |
1891 | Omega-3 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 7件: 13 13, 46, 49, 66, 79, 96, 299 💬 |
1892 | Omega-3 and Vitamin E supplementation | 2件: Omega-3 fatty acids Omega-3 fatty acids, Vitamin E | 1件: Vitamin E
Vitamin E
💬 | - | - | 1件: 46 46 💬 |
1893 | Omega-3 fatty acid | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 46 46, 66 💬 |
1894 | Omega-3 fatty acid ethylester90 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 66 66 💬 |
1895 | Omega-3 Fatty Acid Fish Oil Supplement | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 66 66 💬 |
1896 | Omega-3 fatty acids | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 13 13, 79 💬 |
1897 | Omega-3 triglycerides | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 💬 |
1898 | OMEGA-3-ACID TRIGLYCERIDES | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 💬 |
1899 | Omeprazole 40 mg | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 96 96 💬 |
1900 | Omeprazole 40mg Capsule | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 299 299 💬 |
1901 | OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 222 222 💬 |
1902 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
1903 | ONO-4059 | - | - | - | - | 1件: 35 35 💬 |
1904 | ONO-4641 | - | - | - | - | 1件: 13 13 💬 |
1905 | ONO-4641/ MSC2430913A | - | - | - | - | 1件: 13 13 💬 |
1906 | ONO-4641/MSC2430913A | - | - | - | - | 1件: 13 13 💬 |
1907 | OPC-41061 | - | - | - | - | 1件: 67 67 💬 |
1908 | OPC-41061 (tolvaptan) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1909 | OPC-6535 | - | - | - | - | 2件: 96 96, 97 💬 |
1910 | OPC-6535 Tablets (drug) | - | - | - | - | 1件: 97 97 💬 |
1911 | OPC-6535(Tetomilast) | 1件: Tetomilast Tetomilast | - | - | - | 2件: 96 96, 97 💬 |
1912 | OPS-2071 300 mg | - | - | - | - | 1件: 96 96 💬 |
1913 | OPS-2071 600 mg | - | - | - | - | 1件: 96 96 💬 |
1914 | Oral Budesonide Suspension (MB-9) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1915 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1916 | Oral SCIO-469 capsule | - | - | - | - | 1件: 46 46 💬 |
1917 | Orfadin oral suspension 4mg/ml | 1件: Nitisinone Nitisinone | 1件: Nitisinone
Nitisinone
💬 | 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 💬 |
1918 | ORM-12471 30mg | - | - | - | - | 1件: 51 51 💬 |
1919 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
1920 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 💬 |
1921 | OsrhAAT 3 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
1922 | OsrhAAT 40 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
1923 | OsrhAAT 60 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
1924 | OSSM-001 | - | - | - | - | 1件: 96 96 💬 |
1925 | OSU 6162 similar to (-)-OSU 6162 | - | - | - | - | 1件: 6 6 💬 |
1926 | OSU6162 similar to (-)-OSU 6162 | - | - | - | - | 2件: 6 6, 8 💬 |
1927 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
1928 | OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 107 107 💬 |
1929 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 💬 |
1930 | Oxygen 40 % | 1件: Oxygen Oxygen | 1件: Oxygen
Oxygen
💬 | - | - | 1件: 85 85 💬 |
1931 | Oxytocin 48IU | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 206 206 💬 |
1932 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1933 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1934 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1935 | P32/98 | - | - | - | - | 1件: 37 37 💬 |
1936 | P32/98 3% | - | - | - | - | 1件: 37 37 💬 |
1937 | P38 (4) Map Kinase Inhibitor | - | - | - | - | 1件: 46 46 💬 |
1938 | P38 Inhibitor (4) | - | - | - | - | 1件: 46 46 💬 |
1939 | P38 Inhibitor (4) 150mg | - | - | - | - | 1件: 46 46 💬 |
1940 | P38 Inhibitor (4) 25mg | - | - | - | - | 1件: 46 46 💬 |
1941 | P38 Inhibitor (4) 300mg | - | - | - | - | 1件: 46 46 💬 |
1942 | P38 Inhibitor (4) 50mg | - | - | - | - | 1件: 46 46 💬 |
1943 | P38 Inhibitor (4) 75mg | - | - | - | - | 1件: 46 46 💬 |
1944 | P38(4) Map Kinase Inhibitor | - | - | - | - | 1件: 46 46 💬 |
1945 | PALOVAROTENE - 3 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1946 | PALOVAROTENE - 4 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1947 | Palovarotene dose level 3 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1948 | Palovarotene dose level 4 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1949 | PALOVAROTENE-3 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1950 | PALOVAROTENE-4 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1951 | Pamrevlumab (FG-3019) | 1件: Pamrevlumab Pamrevlumab | 1件: Pamrevlumab
Pamrevlumab
💬 | 1件: CCN2 CCN2 💬 | 2件: Apelin signaling pathway Apelin signaling pathway, Hippo signaling pathway 💬 | 1件: 113 113 💬 |
1952 | Panzytrat 25.000 | - | - | - | - | 1件: 298 298 💬 |
1953 | Panzytrat 25.000 FIP-E units of Lipase | - | - | - | - | 1件: 298 298 💬 |
1954 | Panzytrat® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1955 | Part 1, JM-010 component Group A | - | - | - | - | 1件: 6 6 💬 |
1956 | Part 1, JM-010 component Group B | - | - | - | - | 1件: 6 6 💬 |
1957 | Part 1, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
1958 | Part 2, JM-010 combination Group A | - | - | - | - | 1件: 6 6 💬 |
1959 | Part 2, JM-010 combination Group B | - | - | - | - | 1件: 6 6 💬 |
1960 | Part 2, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
1961 | Part I - etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1962 | Part I - etoricoxib 90 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1963 | Part II- etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1964 | Part II- etoricoxib 90 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1965 | Pasireotida 300 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1966 | Pasireotida 600 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1967 | Pasireotida 900 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1968 | Pasireotide 0.3mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1969 | Pasireotide 0.6 MG/ML | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1970 | Pasireotide 0.6mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1971 | Pasireotide 0.9 mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1972 | Pasireotide 40mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1973 | Pasireotide 60mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1974 | PAT-001, 0.1% | - | - | - | - | 1件: 160 160 💬 |
1975 | PAT-001, 0.2% | - | - | - | - | 1件: 160 160 💬 |
1976 | PBF-677 | - | - | - | - | 1件: 97 97 💬 |
1977 | PBF-999 | - | - | - | - | 1件: 8 8 💬 |
1978 | PBF-999 / 160 mg | - | - | - | - | 1件: 8 8 💬 |
1979 | PBF-999 / 320 mg | - | - | - | - | 1件: 8 8 💬 |
1980 | PD 0299685 | - | - | - | - | 1件: 226 226 💬 |
1981 | PD 0299685 at 15mg BID | - | - | - | - | 1件: 226 226 💬 |
1982 | PD 0299685 at 30mg BID | - | - | - | - | 1件: 226 226 💬 |
1983 | PD 0360324 | - | - | - | - | 2件: 46 46, 84 💬 |
1984 | PD patients H&Y=3 Medications OFF | - | - | - | - | 1件: 6 6 💬 |
1985 | PD patients H&Y=3 Medications ON | - | - | - | - | 1件: 6 6 💬 |
1986 | PD-0299685 | 1件: PD-0299685 PD-0299685 | - | - | - | 1件: 226 226 💬 |
1987 | PD-0325901 | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1988 | Pelubiprofen 30 mg | 1件: Pelubiprofen Pelubiprofen | 1件: Pelubiprofen
Pelubiprofen
💬 | - | - | 1件: 46 46 💬 |
1989 | Pentasa 2g sachet prolonged release granules (95%) | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1990 | Pentasa Compact 4g, granulate with prolonged release | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1991 | Pentoxifylline 400 MG | 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline
Pentoxifylline
💬 | - | - | 1件: 97 97 💬 |
1992 | PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
1993 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 💬 |
1994 | PF-00547659 | - | - | - | - | 2件: 96 96, 97 💬 |
1995 | PF-00547659 SC injection | - | - | - | - | 2件: 96 96, 97 💬 |
1996 | PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
1997 | PF-04171327 | - | - | - | - | 1件: 46 46 💬 |
1998 | PF-04171327 10 mg | - | - | - | - | 1件: 46 46 💬 |
1999 | PF-04171327 25 mg | - | - | - | - | 1件: 46 46 💬 |
2000 | PF-04236921 | - | - | - | - | 2件: 49 49, 96 💬 |
2001 | PF-04236921 SC injection | - | - | - | - | 1件: 96 96 💬 |
2002 | PF-04383119 | - | - | - | - | 1件: 226 226 💬 |
2003 | PF-05208763 | - | - | - | - | 1件: 67 67 💬 |
2004 | PF-05230917 | - | - | - | - | 1件: 97 97 💬 |
2005 | PF-05280586 | - | - | - | - | 1件: 46 46 💬 |
2006 | PF-05285401 | - | - | - | - | 1件: 97 97 💬 |
2007 | PF-06252616 | 1件: Domagrozumab Domagrozumab | 1件: Domagrozumab
Domagrozumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
2008 | PF-06291826-83/Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
2009 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2010 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2011 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2012 | PF-06410293 | - | - | - | - | 1件: 46 46 💬 |
2013 | PF-06412562 | - | - | - | - | 1件: 6 6 💬 |
2014 | PF-06438179 | - | - | - | - | 1件: 46 46 💬 |
2015 | PF-06462700 | - | - | - | - | 1件: 60 60 💬 |
2016 | PF-06480605 | - | - | - | - | 1件: 97 97 💬 |
2017 | PF-06480605 100 mg/ml | - | - | - | - | 1件: 97 97 💬 |
2018 | PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2019 | PF-06649751 - 15mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2020 | PF-06649751 - 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2021 | PF-06649751 - 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2022 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2023 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2024 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2025 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2026 | PF-06650833 | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2027 | PF-06650833 100 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2028 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2029 | PF-06651600 | 1件: PF-06651600 PF-06651600 | - | - | - | 3件: 46 46, 96, 97 💬 |
2030 | PF-06651600 10 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 97 97 💬 |
2031 | PF-06651600 50 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
2032 | PF-06651600 50mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 96 96 💬 |
2033 | PF-06651600-15 | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
2034 | PF-06669571 | - | - | - | - | 1件: 6 6 💬 |
2035 | PF-06687234 | - | - | - | - | 1件: 97 97 💬 |
2036 | PF-06700841 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2037 | PF-06700841 15 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2038 | PF-06700841 25 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 2件: 96 96, 97 💬 |
2039 | PF-06700841 25mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2040 | PF-06700841 30 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2041 | PF-06700841 45 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2042 | PF-06700841 5 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2043 | PF-06700841 5mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2044 | PF-06700841-15 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2045 | PF-06730512 | - | - | - | - | 1件: 222 222 💬 |
2046 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 💬 |
2047 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 💬 |
2048 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 💬 |
2049 | PF-06823859 | - | - | - | - | 1件: 50 50 💬 |
2050 | PF-06823859 high | - | - | - | - | 1件: 50 50 💬 |
2051 | PF-06823859 low | - | - | - | - | 1件: 50 50 💬 |
2052 | PF-06826647 | - | - | - | - | 1件: 97 97 💬 |
2053 | PF-06826647 100 mg QD | - | - | - | - | 1件: 97 97 💬 |
2054 | PF-06826647 300 mg QD | - | - | - | - | 1件: 97 97 💬 |
2055 | PF-06826647 600 mg QD | - | - | - | - | 1件: 97 97 💬 |
2056 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 💬 |
2057 | PF-06836922 | - | - | - | - | 1件: 78 78 💬 |
2058 | PF-06939926 | - | - | - | - | 1件: 113 113 💬 |
2059 | PF-07054894 | - | - | - | - | 1件: 97 97 💬 |
2060 | PF-07256472 | - | - | - | - | 1件: 276 276 💬 |
2061 | PF-6826647 400 mg QD | - | - | - | - | 1件: 97 97 💬 |
2062 | Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
2063 | Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid | - | - | - | - | 1件: 6 6 💬 |
2064 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
2065 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
2066 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
2067 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
2068 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
2069 | PHA-794,428 | - | - | - | - | 1件: 78 78 💬 |
2070 | Phase 2a, SQY51 (cohort 3) | - | - | - | - | 1件: 113 113 💬 |
2071 | Phase 3 | - | - | - | - | 1件: 13 13 💬 |
2072 | Phase2 and 3 : | - | - | - | - | 1件: 96 96 💬 |
2073 | PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
2074 | PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid | - | - | - | - | 1件: 6 6 💬 |
2075 | Phosphorodiamidate morpholino oligomer for exon 45 skipping | - | - | - | - | 1件: 113 113 💬 |
2076 | PHP-303 | - | - | - | - | 1件: 231 231 💬 |
2077 | PI-0824 | 1件: PI-0824 PI-0824 | - | - | - | 1件: 35 35 💬 |
2078 | Pimozide 2mg/day (current) or 4 mg/day (study initiation) | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
2079 | Pimozide 4 mg per day | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
2080 | PIPE-307 | - | - | - | - | 1件: 13 13 💬 |
2081 | Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
2082 | Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
2083 | PL 00095/5079R | - | - | - | - | 1件: 46 46 💬 |
2084 | PL 0010/0211 | - | - | - | - | 1件: 299 299 💬 |
2085 | PL 00512/0150 | - | - | - | - | 1件: 298 298 💬 |
2086 | PL 04515/0127 | - | - | - | - | 1件: 13 13 💬 |
2087 | PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 57 57 💬 |
2088 | PL 12762/0049 | - | - | - | - | 1件: 13 13 💬 |
2089 | PL 17901/0122 | - | - | - | - | 1件: 96 96 💬 |
2090 | PL 20532/0012 | - | - | - | - | 1件: 96 96 💬 |
2091 | PLA-695 | - | - | - | - | 1件: 46 46 💬 |
2092 | PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml | - | - | - | - | 1件: 51 51 💬 |
2093 | PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿ | - | - | - | - | 1件: 51 51 💬 |
2094 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2095 | Plegridy 63 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2096 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
2097 | PLN-74809-000 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
2098 | PLN-74809-020 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
2099 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
2100 | Plovamer acetate 3 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
2101 | PMG1015 Dose 3 | - | - | - | - | 1件: 85 85 💬 |
2102 | PMG1015 Dose 4 | - | - | - | - | 1件: 85 85 💬 |
2103 | PMG1015 Dose 6 | - | - | - | - | 1件: 85 85 💬 |
2104 | PN-943 | - | - | - | - | 1件: 97 97 💬 |
2105 | Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | - | - | - | - | 1件: 46 46 💬 |
2106 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | - | - | - | - | 1件: 46 46 💬 |
2107 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F | - | - | - | - | 1件: 222 222 💬 |
2108 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
2109 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
2110 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1) | 2件: Diethyl ether Diethyl ether, Teriparatide | 2件: Ether
Ether
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2111 | Polyethylene Glycol 3350 | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 2件: 96 96, 299 💬 |
2112 | Pomalidomide (CC-4047 | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
2113 | Pomalidomide (CC-4047) | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 51 51 💬 |
2114 | Ponesimod 40 mg | 1件: Ponesimod Ponesimod | 1件: Ponesimod
Ponesimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2115 | Posaconazole 40 MG/ML | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2116 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
2117 | Postoperative 3-month exclusive enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
2118 | PR-06410293 | - | - | - | - | 1件: 46 46 💬 |
2119 | PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
2120 | PRALIA 60mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
2121 | Pramipexole 0.125 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2122 | Pramipexole 0.5 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2123 | Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2124 | Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2125 | Prednisolone 40 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2126 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2127 | Prednisone 3 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2128 | Prednisone 4 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2129 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 30 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 💬 |
2130 | PREFOLIC 15*30CPR GASTROR 15MG | - | - | - | - | 1件: 337 337 💬 |
2131 | PREFOLIC*30CPR GASTROR 15MG | - | - | - | - | 1件: 299 299 💬 |
2132 | Preparative regimen 4-6 weeks after Leukapheresis | - | - | - | - | 1件: 96 96 💬 |
2133 | PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
2134 | Pridopidine (90 mg) | 1件: Pridopidine Pridopidine | 1件: Pridopidine
Pridopidine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
2135 | PRO044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
2136 | PRO044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
2137 | PRO044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
2138 | PRO045, 0.15 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2139 | PRO045, 1.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2140 | PRO045, 3.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2141 | PRO045, 6.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2142 | PRO045, 9.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2143 | Probiotic - VSL#3 | - | - | - | - | 1件: 96 96 💬 |
2144 | PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
2145 | Products containing azathioprine or 6-mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 97 97 💬 |
2146 | Prolastin-C, 60 mg/kg | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
2147 | PROMIXIN*NEBUL 30MONOD 1MUI | - | - | - | - | 1件: 299 299 💬 |
2148 | Propranolol HCl CF 40 mg tablet | 1件: Propranolol Propranolol | 1件: Propranolol
Propranolol
💬 | 3件: ADRB1 ADRB1, ADRB2, ADRB3 💬 | 12件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2149 | PROSCAR*30CPR RIV 5MG | 1件: Finasteride Finasteride | 1件: Finasteride
Finasteride
💬 | 1件: SRD5A2 SRD5A2 💬 | 3件: Metabolic pathways Metabolic pathways, Prostate cancer, Steroid hormone biosynthesis 💬 | 1件: 6 6 💬 |
2150 | Prototype capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
2151 | PROVIGIL - 100 MG COMPRESSE 30 COMPRESSE | 1件: Modafinil Modafinil | 1件: Modafinil
Modafinil
💬 | - | - | 1件: 113 113 💬 |
2152 | PRTX-100 at 12.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2153 | PRTX-100 at 3.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2154 | PRTX-100 at 420 mcg | - | - | - | - | 1件: 46 46 💬 |
2155 | PRTX-100 at 6.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2156 | PRV-300 | - | - | - | - | 1件: 97 97 💬 |
2157 | PRV-6527 | - | - | - | - | 1件: 96 96 💬 |
2158 | PRV-6527 (JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
2159 | PRV-6527(JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
2160 | PRX-102 2 mg/kg every 4 weeks | - | - | - | - | 1件: 19 19 💬 |
2161 | Pseudoephedrine + 480 ml water | 2件: Pseudoephedrine Pseudoephedrine, Water | 2件: Water
Water
,
Pseudoephedrine
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
2162 | PT320 2.0 mg | - | - | - | - | 1件: 6 6 💬 |
2163 | PTC-0161480 | - | - | - | - | 2件: 246 246, 299 💬 |
2164 | PTH 1-34 | 1件: Teriparatide Teriparatide | 1件: Teriparatide
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 2件: 65 65, 235 💬 |
2165 | PTI-428 | 1件: PTI-428 PTI-428 | - | - | - | 1件: 299 299 💬 |
2166 | PTR-01 | - | - | - | - | 1件: 36 36 💬 |
2167 | PTW-002 10 mg/g gel | - | - | - | - | 1件: 36 36 💬 |
2168 | Puerarin injection 400 mg | 1件: Puerarin Puerarin | - | - | - | 1件: 46 46 💬 |
2169 | PUR 0110 | - | - | - | - | 1件: 97 97 💬 |
2170 | PUR 0110 Rectal Enema | - | - | - | - | 1件: 97 97 💬 |
2171 | PUR 0110 Rectal Enema 1000 mg | - | - | - | - | 1件: 97 97 💬 |
2172 | PUR 0110 Rectal Enema 250 mg | - | - | - | - | 1件: 97 97 💬 |
2173 | PUR 0110 Rectal Enema 500 mg | - | - | - | - | 1件: 97 97 💬 |
2174 | Q4W GMA301 IV injections (300 mg) | - | - | - | - | 1件: 86 86 💬 |
2175 | Q4W GMA301 IV injections (600 mg) | - | - | - | - | 1件: 86 86 💬 |
2176 | QBW276 300mcg | - | - | - | - | 1件: 299 299 💬 |
2177 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 💬 |
2178 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 💬 |
2179 | Qingkailing injection 40 ml | - | - | - | - | 1件: 46 46 💬 |
2180 | QLS-101 ophthalmic solution, 2.0 % | - | - | - | - | 1件: 157 157 💬 |
2181 | QR-010 | - | - | - | - | 1件: 299 299 💬 |
2182 | QR-313 | - | - | - | - | 1件: 36 36 💬 |
2183 | QR-313 Gel for Topical (Cutaneous) Administration | - | - | - | - | 1件: 36 36 💬 |
2184 | QR-421a | - | - | - | - | 2件: 90 90, 303 💬 |
2185 | QRL-201 - Dose 3 | - | - | - | - | 1件: 2 2 💬 |
2186 | QRL-201 - Dose 4 | - | - | - | - | 1件: 2 2 💬 |
2187 | QRL-201 - Dose 6 | - | - | - | - | 1件: 2 2 💬 |
2188 | QTXEW2-04-AF, EW2, GC-1, QRX-431 | - | - | - | - | 1件: 20 20 💬 |
2189 | R-021 | - | - | - | - | 1件: 222 222 💬 |
2190 | R-3750 | - | - | - | - | 1件: 97 97 💬 |
2191 | R788 sodium hexahydrate, RIG2-01, RIG-G | - | - | - | - | 1件: 46 46 💬 |
2192 | RAAV 2/6 hIDS DONOR | - | - | - | - | 1件: 19 19 💬 |
2193 | RAAV2/5-PBGD vector dosage 3 | - | - | - | - | 1件: 254 254 💬 |
2194 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 💬 |
2195 | RAAV2/6 Left ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
2196 | RAAV2/6 Right ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
2197 | Radiolabelled OligoG CF-5/20 6% Solution | - | - | - | - | 1件: 299 299 💬 |
2198 | Radiolabelled OligoG CF-5/20 6% Solution for Nebulisation | - | - | - | - | 1件: 299 299 💬 |
2199 | RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2200 | RANEXA*60CPR 500MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2201 | RANEXA*60CPR 750MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2202 | Ranibizumab injection (0.5 mg) | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 2件: 166 166, 301 💬 |
2203 | RAPAMUNE*30CPR RIV 1MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
2204 | RAPAMUNE*30CPR RIV 2MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
2205 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2206 | Rasagiline mesylate 1.0 mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2207 | RAvPAL-PEG 0.001 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2208 | RAvPAL-PEG 0.003 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2209 | RAvPAL-PEG 0.01 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2210 | RAvPAL-PEG 0.03 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2211 | RAvPAL-PEG 0.1 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2212 | RCTB-401 | - | - | - | - | 1件: 96 96 💬 |
2213 | RE-021 | - | - | - | - | 3件: 66 66, 218, 222 💬 |
2214 | RE-021 (Sparsentan) | 1件: Sparsentan Sparsentan | 1件: Sparsentan
Sparsentan
💬 | 2件: AGTR1 AGTR1, EDNRA 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2215 | RE-024 | - | - | - | - | 1件: 120 120 💬 |
2216 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2217 | Rebif 22 y 44 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2218 | Rebif 44 | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2219 | Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2220 | REBIF 44 microgramos solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2221 | REBIF 44 microgramos solución inyectable en jeringa precargada | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2222 | Rebif 44 micrograms | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2223 | Rebif 44 micrograms solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2224 | Rebif 44 micrograms solution for injection in pre-filled syringe | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2225 | Rebif 44 µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2226 | Rebif 44® | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2227 | Rebif New Formulation 44mcg multidose cartridge | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2228 | REBIF SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2229 | REBIF*SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2230 | Rebif® (clone 484-39) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2231 | Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4) | 1件: NADH NADH | - | - | - | 1件: 302 302 💬 |
2232 | Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galactosidase A | - | - | - | - | 1件: 19 19 💬 |
2233 | Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 107 107 💬 |
2234 | RECOMBINANT HUMAN ?-GLUCOSIDASE CONJUGATED WITH SYNTHETIC BISMANNOSE-6-PHOSPHATE-MAN6 GLYCAN | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 256 256 💬 |
2235 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (NEOGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
2236 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan Avalglucosidase Alfa (NeoGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
2237 | RECOMBINANT HUMAN ALFA-GLUCOSIDASE CONJUGATED WITH SYNTHETIC BISMANNOSE-6-PHOSPHATE-MAN6 GLYCAN | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 256 256 💬 |
2238 | Recombinant human Arysulfatase B, recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
2239 | Recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
2240 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 | - | - | - | - | 1件: 19 19 💬 |
2241 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 drug substance | - | - | - | - | 1件: 19 19 💬 |
2242 | Recombinant human N-acetylgalactosamine-6-sulfatase | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2243 | Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2244 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2245 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 drug substance | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2246 | Recombinant humanised anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 46 46 💬 |
2247 | Recombinant humanized anti-alpha 4 integrin antibody | - | - | - | - | 1件: 13 13 💬 |
2248 | Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal | - | - | - | - | 1件: 46 46 💬 |
2249 | Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
2250 | Recombinant humanized anti-human Interleukin-6 | - | - | - | - | 1件: 46 46 💬 |
2251 | Recombinant humanized anti-human Interleukin-6 Receptor (IL-6R) monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
2252 | Recombinant humanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 3件: 46 46, 51, 107 💬 |
2253 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 331 331 💬 |
2254 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg | - | - | - | - | 1件: 331 331 💬 |
2255 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg | - | - | - | - | 1件: 331 331 💬 |
2256 | Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene | - | - | - | - | 1件: 19 19 💬 |
2257 | Recombinant von Willebrand Factor 650IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2258 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
2259 | Reference capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
2260 | Regimen Selection Phase Group 3 | - | - | - | - | 1件: 113 113 💬 |
2261 | REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | - | - | - | - | 1件: 79 79 💬 |
2262 | Reldesemtiv 450 mg | 1件: Reldesemtiv Reldesemtiv | 1件: Reldesemtiv
Reldesemtiv
💬 | 1件: TNNC2 TNNC2 💬 | 1件: Calcium signaling pathway Calcium signaling pathway 💬 | 1件: 3 3 💬 |
2263 | Repatha 420 mg solution for injection in cartridge | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
2264 | Repatha 420 mg soluzione per iniezione in cartuccia | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
2265 | REQUIP 21 CPR 0,25 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2266 | REQUIP 21 CPR 0,5 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2267 | Requip Modutab, 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2268 | REQUIP*21CPR 0,25MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2269 | REQUIP*21CPR 0,5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2270 | REQUIP-MODUTAB , 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2271 | REQUIP-MODUTAB, 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2272 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
2273 | Revatio 0.8mg/ml solution for injection | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
2274 | REYATAZ 150MG 60 CPS BL | 1件: Atazanavir Atazanavir | 1件: Atazanavir
Atazanavir
💬 | - | - | 1件: 265 265 💬 |
2275 | RG-012 | - | - | - | - | 1件: 218 218 💬 |
2276 | RG2133 (2',3',5'-tri-O-acetyluridine) | 1件: Uridine triacetate Uridine triacetate | 1件: Uridine triacetate
Uridine triacetate
💬 | - | - | 1件: 21 21 💬 |
2277 | RG6042, formerly ISIS 443139, IONIS-HTTRx | - | - | - | - | 1件: 8 8 💬 |
2278 | RGB-03 | - | - | - | - | 1件: 46 46 💬 |
2279 | RhASA - Dose Level 3 | - | - | - | - | 1件: 19 19 💬 |
2280 | RhGH Norditropin® pen (34 µg/kg) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2281 | RhHNS-45 mg | - | - | - | - | 1件: 19 19 💬 |
2282 | RhHNS-90 mg | - | - | - | - | 1件: 19 19 💬 |
2283 | RhIGF-1/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 195 195 💬 |
2284 | RhIGF-I/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 113 113 💬 |
2285 | RhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 2件: 113 113, 195 💬 |
2286 | RhNGF 60 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
2287 | RhPTH (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
2288 | RhuDex 25 mg (31.75 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
2289 | RhuDex 50 mg (63.5 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
2290 | Rhustoxicodendron 30 | - | - | - | - | 1件: 46 46 💬 |
2291 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
2292 | Rifampin 300mg BID + istradefylline 40mg Day 8 only | 2件: Istradefylline Istradefylline, Rifampicin | 2件: Rifampin
Rifampin
,
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2293 | Rifaximin delayed release 400 mg film coated tablet | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 96 96 💬 |
2294 | RILUZOLO TEVA - 50 MG COMPRESSE RIVESTITE CON FILM 90 COMPRESSE IN BLISTER AL/PVC | - | - | - | - | 1件: 114 114 💬 |
2295 | Riociguat coated tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2296 | Riociguat coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2297 | Riociguat coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2298 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2299 | Risankizumab 600 mg IV | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
2300 | Risankizumab 90 mg/ml | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
2301 | Ritalin LA 30mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2302 | Ritalin LA 40mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2303 | Ritlecitinib/JAK 3 | - | - | - | - | 1件: 46 46 💬 |
2304 | Rituximab-Pfizer (PF-05280586) x 3 courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2305 | RIV-TDS 13.3 mg/24 h | - | - | - | - | 1件: 6 6 💬 |
2306 | Rivastigmin Luye Transdermal Patches - 4.6mg/24h | - | - | - | - | 1件: 6 6 💬 |
2307 | Rivastigmine Luye Transdermal Patch- 9.5mg/24h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2308 | Rivastigmine Patch 9.5 cm2 | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2309 | Rivastigmine transdermal system 13.3 mg/24 h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2310 | RM-493 | - | - | - | - | 2件: 193 193, 202 💬 |
2311 | Ro 001-9265 | - | - | - | - | 1件: 41 41 💬 |
2312 | Ro 001-9265/F02 | - | - | - | - | 1件: 41 41 💬 |
2313 | RO 001-9265/F02-01 | - | - | - | - | 1件: 46 46 💬 |
2314 | Ro 001-9265/F03 | - | - | - | - | 1件: 41 41 💬 |
2315 | Ro 001-9265/F04 | - | - | - | - | 1件: 41 41 💬 |
2316 | Ro 002-9893/F02 | - | - | - | - | 1件: 46 46 💬 |
2317 | Ro 45-2294 | - | - | - | - | 1件: 46 46 💬 |
2318 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 💬 |
2319 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
2320 | Ro 48-77533 | - | - | - | - | 1件: 46 46 💬 |
2321 | Ro 487-533/F01 | - | - | - | - | 1件: 271 271 💬 |
2322 | Ro 487-5733/F01 | - | - | - | - | 1件: 271 271 💬 |
2323 | RO 487-7533 | - | - | - | - | 1件: 46 46 💬 |
2324 | Ro 487-7533/F01 | - | - | - | - | 3件: 46 46, 107, 271 💬 |
2325 | Ro 487-7533/F10 | - | - | - | - | 2件: 46 46, 107 💬 |
2326 | Ro 487-7533/F10-02 | - | - | - | - | 1件: 46 46 💬 |
2327 | Ro 487-7533/F10-04 | - | - | - | - | 4件: 41 41, 46, 51, 107 💬 |
2328 | Ro 491-7523/F18 | - | - | - | - | 1件: 206 206 💬 |
2329 | Ro 491-7523/F19 | - | - | - | - | 1件: 206 206 💬 |
2330 | RO 496-4913 | - | - | - | - | 2件: 46 46, 49 💬 |
2331 | Ro 496-4913/F03 | - | - | - | - | 2件: 13 13, 46 💬 |
2332 | Ro 496-4913/F07 | - | - | - | - | 1件: 13 13 💬 |
2333 | Ro 533-3787/F01- 06 | - | - | - | - | 1件: 13 13 💬 |
2334 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 💬 |
2335 | Ro 549-0261/F04 | - | - | - | - | 1件: 97 97 💬 |
2336 | Ro 549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
2337 | Ro 549-0261/F08-02 | - | - | - | - | 1件: 96 96 💬 |
2338 | RO 551-6922 | - | - | - | - | 1件: 46 46 💬 |
2339 | Ro 723-4292/F02 | - | - | - | - | 1件: 8 8 💬 |
2340 | Ro-47-0203 | - | - | - | - | 1件: 86 86 💬 |
2341 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 💬 |
2342 | RO-496-4913 | - | - | - | - | 1件: 46 46 💬 |
2343 | RO001-9265/F04 | - | - | - | - | 1件: 46 46 💬 |
2344 | Ro47-0203 | - | - | - | - | 1件: 86 86 💬 |
2345 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
2346 | RO487-7533/F10-04 | - | - | - | - | 2件: 46 46, 51 💬 |
2347 | RO4917523 0.5 mg | - | - | - | - | 1件: 206 206 💬 |
2348 | RO496-4913 | - | - | - | - | 1件: 46 46 💬 |
2349 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 💬 |
2350 | RO545-9072/F03 | - | - | - | - | 1件: 53 53 💬 |
2351 | Ro549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
2352 | RO5490255/F01-02 | - | - | - | - | 1件: 85 85 💬 |
2353 | RO5490261/F04-02 | - | - | - | - | 1件: 97 97 💬 |
2354 | RO7112689/F03-01 | - | - | - | - | 2件: 62 62, 109 💬 |
2355 | RO7123520/F03-01 | - | - | - | - | 1件: 46 46 💬 |
2356 | RO7204239/F01-01 | - | - | - | - | 1件: 3 3 💬 |
2357 | RO7239361 (BMS-986089) | - | - | - | - | 1件: 113 113 💬 |
2358 | RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2359 | RO7239361 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2360 | RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2361 | RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
2362 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
2363 | RO7490677 320 mg/16 ml (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
2364 | RO7490677 320mg/16mL (1st generation) | - | - | - | - | 1件: 85 85 💬 |
2365 | RO7490677 320mg/16mL (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
2366 | RO7490677/ F01-02 | - | - | - | - | 1件: 85 85 💬 |
2367 | RO7490677/F01-01 | - | - | - | - | 1件: 85 85 💬 |
2368 | RO7490677/F01-02 | - | - | - | - | 1件: 85 85 💬 |
2369 | RO7490677/F01-03 | - | - | - | - | 1件: 85 85 💬 |
2370 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
2371 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2372 | Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali | - | - | - | - | 1件: 46 46 💬 |
2373 | Rob 803 (capsules 6.25 mg) | - | - | - | - | 1件: 46 46 💬 |
2374 | Rob 803 6.25mg capsule | - | - | - | - | 1件: 46 46 💬 |
2375 | Rob 803 6.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
2376 | Rodatristat ethyl 300 mg tablet BID | - | - | - | - | 1件: 86 86 💬 |
2377 | Rodatristat ethyl 600 mg BID | - | - | - | - | 1件: 86 86 💬 |
2378 | Roferon-A 3miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2379 | Roferon-A, 3miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2380 | Roferon-A, 4.5miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2381 | Roferon-A, 6miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2382 | Rosuvastatin calcium 40mg | 2件: Calcium Calcium, Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 56 56 💬 |
2383 | Rotigotine (Test product PR 2.3.1) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2384 | Rotigotine transdermal patch 4mg/24h (20cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2385 | Rotigotine transdermal patch 6mg/24h (30cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2386 | Rotigotine transdermal patch 8mg/24h (40cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2387 | RQ-00000010 | - | - | - | - | 1件: 6 6 💬 |
2388 | RST-001 | - | - | - | - | 1件: 90 90 💬 |
2389 | RTA 402 | - | - | - | - | 3件: 67 67, 86, 218 💬 |
2390 | RVG 03820 | - | - | - | - | 1件: 3 3 💬 |
2391 | RVG 05565 | - | - | - | - | 1件: 96 96 💬 |
2392 | RVG 07151 | - | - | - | - | 1件: 96 96 💬 |
2393 | RVG 08740 | - | - | - | - | 1件: 6 6 💬 |
2394 | RVG 08938 | - | - | - | - | 1件: 75 75 💬 |
2395 | RVG 33865 | - | - | - | - | 1件: 86 86 💬 |
2396 | RVT-101 35 mg | - | - | - | - | 1件: 6 6 💬 |
2397 | RWJ-445380 100 mg | - | - | - | - | 1件: 46 46 💬 |
2398 | RWJ-445380 200 mg | - | - | - | - | 1件: 46 46 💬 |
2399 | RWJ-445380 300 mg | - | - | - | - | 1件: 46 46 💬 |
2400 | RWJ-445380 capsule 100 mg | - | - | - | - | 1件: 46 46 💬 |
2401 | RWJ-445380 capsules 150 mg | - | - | - | - | 1件: 46 46 💬 |
2402 | RWJ-445380 Capsules 50 mg | - | - | - | - | 1件: 46 46 💬 |
2403 | RWJ-445380-002 | - | - | - | - | 1件: 46 46 💬 |
2404 | S 90049 | - | - | - | - | 1件: 6 6 💬 |
2405 | S 90049 - F36 | - | - | - | - | 1件: 6 6 💬 |
2406 | S 90049 - F38 | - | - | - | - | 1件: 6 6 💬 |
2407 | S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide | - | - | - | - | 1件: 46 46 💬 |
2408 | SA-001 | - | - | - | - | 1件: 298 298 💬 |
2409 | SAF-301 | - | - | - | - | 1件: 19 19 💬 |
2410 | Salbutamol 4Mg Tablet | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
2411 | Salbutamol WZF 4 mg | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
2412 | Saline 0.9% inhalation solution | - | - | - | - | 1件: 299 299 💬 |
2413 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
2414 | Salofalk 3g gastro-resistant prolonged-release granules | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2415 | Salofalk 4g/60ml Klysma | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2416 | Samsca 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2417 | SAN-300 0.5 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2418 | SAN-300 1.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2419 | SAN-300 2.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
2420 | SAN-300 4.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
2421 | SAN-300 4.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2422 | SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2423 | SANDIMMUN NEORAL*30CPS 100MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2424 | Sapropterin dihydrochloride (6R-BH4) | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 86 86 💬 |
2425 | Sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
2426 | Saroglitazar magnesium 4 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 💬 |
2427 | SB 681323 | - | - | - | - | 1件: 46 46 💬 |
2428 | SB-318 | - | - | - | - | 1件: 19 19 💬 |
2429 | SB-47171 | - | - | - | - | 1件: 19 19 💬 |
2430 | SB-47898 | - | - | - | - | 1件: 19 19 💬 |
2431 | SB-497115 | - | - | - | - | 1件: 63 63 💬 |
2432 | SB-497115-GR | - | - | - | - | 1件: 63 63 💬 |
2433 | SB-497115-GR 12.5mg | - | - | - | - | 1件: 63 63 💬 |
2434 | SB-497115-GR 25mg | - | - | - | - | 1件: 63 63 💬 |
2435 | SB-497115-GR 50 mg | - | - | - | - | 1件: 63 63 💬 |
2436 | SB-656933 | - | - | - | - | 1件: 97 97 💬 |
2437 | SB-656933 Tablets | - | - | - | - | 2件: 97 97, 299 💬 |
2438 | SB-656933-AAA | - | - | - | - | 1件: 299 299 💬 |
2439 | SB-681323 | - | - | - | - | 1件: 46 46 💬 |
2440 | SB-681323 oral tablets | - | - | - | - | 1件: 46 46 💬 |
2441 | SB-681323 Tablets | - | - | - | - | 1件: 46 46 💬 |
2442 | SB-683699 | - | - | - | - | 1件: 13 13 💬 |
2443 | SB-913 | - | - | - | - | 1件: 19 19 💬 |
2444 | SBI-087 | - | - | - | - | 2件: 46 46, 49 💬 |
2445 | SBT-020 | - | - | - | - | 1件: 8 8 💬 |
2446 | SC12267 (4SC-101) | 1件: SC12267 SC12267 | - | - | - | 3件: 46 46, 96, 97 💬 |
2447 | SCH 420814 | - | - | - | - | 1件: 6 6 💬 |
2448 | SCH 420814 10 mg | - | - | - | - | 1件: 6 6 💬 |
2449 | SCH 420814 100 mg | - | - | - | - | 1件: 6 6 💬 |
2450 | SCH 900050 | - | - | - | - | 1件: 97 97 💬 |
2451 | SCH 900259 | - | - | - | - | 1件: 46 46 💬 |
2452 | SCH 900800 | - | - | - | - | 1件: 6 6 💬 |
2453 | SCIO-469 | - | - | - | - | 1件: 46 46 💬 |
2454 | SCM-010 | - | - | - | - | 1件: 13 13 💬 |
2455 | SD-101 dermal cream (3%) | - | - | - | - | 1件: 36 36 💬 |
2456 | SD-101 Dermal Cream (6%) | - | - | - | - | 1件: 36 36 💬 |
2457 | SD-101-6.0 cream | - | - | - | - | 1件: 36 36 💬 |
2458 | Search for exocrine pancreatic insufficiency at week 0 and 12 | - | - | - | - | 1件: 96 96 💬 |
2459 | Sebelipase alfa 0.35 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
2460 | Sebelipase alfa 3 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
2461 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
2462 | Secukinumab 300 mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
2463 | Secukinumab 300 mg, s.c. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
2464 | Secukinumab 300mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬 |
2465 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
2466 | See D.3.9.3 'Other descriptive name' below | - | - | - | - | 1件: 46 46 💬 |
2467 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2468 | SEP-363856 | 1件: SEP-363856 SEP-363856 | - | - | - | 1件: 6 6 💬 |
2469 | Serum physiologique 0.9 % | - | - | - | - | 1件: 96 96 💬 |
2470 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
2471 | SGT-001 | - | - | - | - | 1件: 113 113 💬 |
2472 | SHP 655 (BAX 930) | - | - | - | - | 1件: 64 64 💬 |
2473 | Sifalimumab 600 mg | 1件: Sifalimumab Sifalimumab | 1件: Sifalimumab
Sifalimumab
💬 | 13件: IFNA1 IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 💬 | 25件: Alcoholic liver disease Alcoholic liver disease, Autoimmune thyroid disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 49 49 💬 |
2474 | Sifrol 0,088 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2475 | Sifrol 0,18 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2476 | Sifrol 0,35 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2477 | Sifrol 0,7 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2478 | Sifrol, 0,35 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2479 | Sifrol, 0,70 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2480 | Sildenafil (Subchronic-4 weeks) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
2481 | Sildenafil 20mg and Bosentan 62.5mg | 2件: Bosentan Bosentan, Sildenafil | 3件: Bosentan
Bosentan
,
Bosentan
,
Sildenafil
💬 | 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
2482 | Sildenafil 40mg oral capsule | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
2483 | Sildenafil citrate (UK-92,480) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2484 | Silikis 3µg/g Salbe | - | - | - | - | 1件: 37 37 💬 |
2485 | SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2486 | SimvaHEXAL® 40 mg Filmtabletten | - | - | - | - | 1件: 13 13 💬 |
2487 | Simvastatin 40 mg | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 💬 |
2488 | Simvastatin 40 mg film-coated tablets | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2489 | Simvastatin 40 mg tablets | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 💬 |
2490 | Simvastatin 40mg | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 94 94 💬 |
2491 | Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2492 | Simvastatine Sandoz 40 mg filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2493 | Simvastatine Sandoz 40mg deelbare filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2494 | Sinvastatina Sandoz 40 mg comprimidos revestidos por película | - | - | - | - | 1件: 13 13 💬 |
2495 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2496 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
2497 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
2498 | SIRIO*30CPR EFF 25MG+100MG | - | - | - | - | 1件: 6 6 💬 |
2499 | Sirolimus 0,1% crème | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
2500 | Sirolimus 0.2% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2501 | Sirolimus 0.4% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2502 | Sirolimus and Hydroxychloroquine 400 mg | 2件: Hydroxychloroquine Hydroxychloroquine, Sirolimus | 2件: Sirolimus
Sirolimus
,
Hydroxychloroquine
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 89 89 💬 |
2503 | Sivatin 40 mg film-coated tablets | - | - | - | - | 1件: 13 13 💬 |
2504 | SKI-606 | - | - | - | - | 1件: 67 67 💬 |
2505 | SLS-005 | - | - | - | - | 1件: 2 2 💬 |
2506 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 💬 |
2507 | SMOFKABIVEN - EMULSIONE PER INFUSIONE SENZA ELETTROLITI 1 SACCA BIOFINE MULTICOMPARTIMENTATE DA 493 ML | 2件: Medium-chain triglycerides Medium-chain triglycerides, Sodium glycerophosphate | 1件: Sodium glycerophosphate
Sodium glycerophosphate
💬 | - | - | 1件: 66 66 💬 |
2508 | SND 919 CL2 Y | - | - | - | - | 1件: 6 6 💬 |
2509 | SND 919 CL2Y | - | - | - | - | 1件: 6 6 💬 |
2510 | Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca | - | - | - | - | 1件: 299 299 💬 |
2511 | Sodium (S)-3-(4-hydroxyphenyl)-2-(2-((S)-1-((S)-1-palmitoylpyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)propanoate | 1件: Pyrrolidine Pyrrolidine | - | - | - | 1件: 97 97 💬 |
2512 | Sodium 4-Phenylbutyrate | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 299 299 💬 |
2513 | Sodium 4-Phenylbutyrate (4PBA) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 299 299 💬 |
2514 | Sodium chloride 0,9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2515 | Sodium Chloride 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 2件: 14 14, 227 💬 |
2516 | Sodium chloride 6% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2517 | SODIUM CHLORIDE SOLUTION 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 51 51, 60, 288, 299 💬 |
2518 | Sodium Pyruvate in 0.9% Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2519 | Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
2520 | Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
2521 | SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML) | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 13 13, 62, 109 💬 |
2522 | Soliris 300 | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2523 | SOLIRIS 300 mg concentrado para solución para perfusión | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 109 109 💬 |
2524 | Soliris 300 mg concentrate for solution for infusion | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2525 | Soliris 300mg/30ml | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2526 | SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML | - | - | - | - | 1件: 56 56 💬 |
2527 | Solu-medrol inj. PSO LQF 40mg | 1件: Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate | 1件: Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 50 50 💬 |
2528 | SOM230 300µg | - | - | - | - | 1件: 75 75 💬 |
2529 | SOM230 600µg | - | - | - | - | 1件: 75 75 💬 |
2530 | SOM230 900µg | - | - | - | - | 1件: 75 75 💬 |
2531 | SOM230 LAR 30 mg | - | - | - | - | 1件: 75 75 💬 |
2532 | SOM230, 300micrograms | - | - | - | - | 1件: 75 75 💬 |
2533 | SOM230, 600 micrograms | - | - | - | - | 1件: 75 75 💬 |
2534 | SOM230, 900 micrograms | - | - | - | - | 1件: 75 75 💬 |
2535 | Somatuline Autogel 90 mg | 1件: Lanreotide Lanreotide | - | - | - | 1件: 298 298 💬 |
2536 | Somavaratan (VRS-317) | 1件: Somavaratan Somavaratan | 1件: Somavaratan
Somavaratan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
2537 | Sotatercept - 45 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
2538 | Sotatercept - 60 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
2539 | SPI-62 | - | - | - | - | 1件: 75 75 💬 |
2540 | SPI-62 dose 2 | - | - | - | - | 1件: 75 75 💬 |
2541 | SPI-62 dose 3 | - | - | - | - | 1件: 75 75 💬 |
2542 | SPI-62 dose 4 | - | - | - | - | 1件: 75 75 💬 |
2543 | SPI-62 dose1 | - | - | - | - | 1件: 75 75 💬 |
2544 | SPK-3006 | - | - | - | - | 1件: 256 256 💬 |
2545 | SPM 926 | - | - | - | - | 1件: 6 6 💬 |
2546 | SPM 962 | - | - | - | - | 1件: 6 6 💬 |
2547 | SPP-004 | - | - | - | - | 1件: 21 21 💬 |
2548 | SRK-015 | - | - | - | - | 1件: 3 3 💬 |
2549 | SRP-4045 | - | - | - | - | 1件: 113 113 💬 |
2550 | SRP-4053 | - | - | - | - | 1件: 113 113 💬 |
2551 | SRP-9001 | - | - | - | - | 1件: 113 113 💬 |
2552 | SRP-9003 | 1件: SRP-9003 SRP-9003 | - | - | - | 1件: 113 113 💬 |
2553 | SRP-9004 | - | - | - | - | 1件: 113 113 💬 |
2554 | SSGJ-613 | - | - | - | - | 1件: 107 107 💬 |
2555 | SSP-004184 100 mg | - | - | - | - | 1件: 284 284 💬 |
2556 | SSP-004184 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2557 | SSP-004184 250 mg | - | - | - | - | 1件: 284 284 💬 |
2558 | SSP-004184 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2559 | SSP-004184 375 mg | - | - | - | - | 1件: 284 284 💬 |
2560 | SSP-004184 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2561 | SSP-004184 50 mg | - | - | - | - | 1件: 284 284 💬 |
2562 | SSP-004184 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2563 | SSP-004184 500 mg | - | - | - | - | 1件: 284 284 💬 |
2564 | SSP-004184 500 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2565 | SSP-004184AQ 100 mg | - | - | - | - | 1件: 284 284 💬 |
2566 | SSP-004184AQ 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2567 | SSP-004184AQ 200 mg | - | - | - | - | 1件: 284 284 💬 |
2568 | SSP-004184AQ 200 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2569 | SSP-004184AQ 250 mg | - | - | - | - | 1件: 284 284 💬 |
2570 | SSP-004184AQ 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2571 | SSP-004184AQ 375 mg | - | - | - | - | 1件: 284 284 💬 |
2572 | SSP-004184AQ 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2573 | SSP-004184AQ 50 mg | - | - | - | - | 1件: 284 284 💬 |
2574 | SSP-004184AQ 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2575 | ST 36 | - | - | - | - | 1件: 49 49 💬 |
2576 | ST-0529 | - | - | - | - | 1件: 97 97 💬 |
2577 | ST-920 | - | - | - | - | 1件: 19 19 💬 |
2578 | ST10-021 | - | - | - | - | 2件: 96 96, 97 💬 |
2579 | STA-6838, STA-5326 m, S38 | - | - | - | - | 1件: 96 96 💬 |
2580 | Stalevo 150/37.5/200 mg | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2581 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
2582 | Standard-dose vitamin D (400IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
2583 | STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2584 | STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2585 | STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 2件: 96 96, 97 💬 |
2586 | STELARA 90 mg solution for injection in pre-filled syringe | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2587 | Stelara 90mg/1ml solution for injecti | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2588 | Stelara 90mg/1ml solution for injection in pre-filled syringe (PFS) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2589 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
2590 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
2591 | STG-001 | 1件: STG-001 STG-001 | - | - | - | 1件: 301 301 💬 |
2592 | STI-6129 | - | - | - | - | 1件: 28 28 💬 |
2593 | STK-001 | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2594 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2595 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2596 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2597 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2598 | Suspension of human autologous MSC 3P in 1,5 ml | - | - | - | - | 1件: 2 2 💬 |
2599 | Suspension of human autologous MSC 3P in 1.5 ml | - | - | - | - | 1件: 2 2 💬 |
2600 | SYN115 Tablets, 60 mg | - | - | - | - | 1件: 6 6 💬 |
2601 | Synthetic Human Parathyroid Hormone 1-34 | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2602 | Syntocinon 40 IU/ml nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2603 | T 614 | - | - | - | - | 1件: 300 300 💬 |
2604 | T-326 | - | - | - | - | 1件: 299 299 💬 |
2605 | T-614 | - | - | - | - | 1件: 46 46 💬 |
2606 | TA-46 | - | - | - | - | 1件: 276 276 💬 |
2607 | TA-650 | - | - | - | - | 4件: 37 37, 56, 96, 97 💬 |
2608 | TA-650 (Infliximab) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 97, 271 💬 |
2609 | TA-650 10 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2610 | TA-650 3 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2611 | TA-650 6 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2612 | TAD 600 | - | - | - | - | 1件: 299 299 💬 |
2613 | Tadalafil 40 mg | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2614 | TAK-018 | - | - | - | - | 1件: 96 96 💬 |
2615 | TAK-071 | - | - | - | - | 1件: 6 6 💬 |
2616 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 💬 |
2617 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 💬 |
2618 | TAK-341 | - | - | - | - | 1件: 17 17 💬 |
2619 | TAK-475 | 1件: TAK-475 TAK-475 | - | - | - | 1件: 79 79 💬 |
2620 | TAK-625 | - | - | - | - | 2件: 297 297, 338 💬 |
2621 | TAK-672 | - | - | - | - | 1件: 288 288 💬 |
2622 | TAK-935 | - | - | - | - | 2件: 140 140, 144 💬 |
2623 | Tamoxifen 40 mg daily for one year | 1件: Tamoxifen Tamoxifen | 1件: Tamoxifen
Tamoxifen
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 2 2 💬 |
2624 | TAP-144-SR(3M) | - | - | - | - | 1件: 1 1 💬 |
2625 | Tavapadon 0.25 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2626 | Tavapadon 0.25mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2627 | Tc 99m tilmanocept | 1件: Tilmanocept Tilmanocept | - | - | - | 1件: 46 46 💬 |
2628 | TD-3504 | - | - | - | - | 1件: 97 97 💬 |
2629 | TD-9855 | - | - | - | - | 2件: 6 6, 17 💬 |
2630 | TECHNETIUM (99MTC) EXAMETAZIME | 2件: Exametazime Exametazime, Technetium Tc-99m exametazime | 1件: Exametazime
Exametazime
💬 | - | - | 1件: 6 6 💬 |
2631 | Technetium Tc 99m | 1件: Technetium Tc-99m Technetium Tc-99m | - | - | - | 1件: 46 46 💬 |
2632 | Technetium Tc 99m Tilmanocept | 3件: Technetium Tc-99m Technetium Tc-99m, Technetium Tc-99m tilmanocept, Tilmanocept | - | - | - | 1件: 46 46 💬 |
2633 | Teduglutide (ALX-0600) | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2634 | Teduglutide 0.05 | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2635 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2636 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2637 | Teduglutide 0.2 mg | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2638 | Tehalose 30gr | - | - | - | - | 1件: 113 113 💬 |
2639 | Terguride 0,5mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
2640 | Terguride 0.5 mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
2641 | Teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) | 2件: Parathyroid hormone Parathyroid hormone, Teriparatide | 2件: Parathyroid hormone
Parathyroid hormone
,
Teriparatide
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
2642 | TETA 4HCL | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2643 | TETA.4HCI | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2644 | TETA.4HCl | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2645 | TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML | - | - | - | - | 1件: 222 222 💬 |
2646 | Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol | - | - | - | - | 1件: 298 298 💬 |
2647 | TEV-48574 | - | - | - | - | 2件: 96 96, 97 💬 |
2648 | TEV-48574 Dose Regimen A | - | - | - | - | 2件: 96 96, 97 💬 |
2649 | TEV-48574 Dose Regiment B | - | - | - | - | 2件: 96 96, 97 💬 |
2650 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
2651 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
2652 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
2653 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
2654 | Thymosin Beta 4 | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 2件: 36 36, 53 💬 |
2655 | Thymosin Beta 4 eye drops | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 1件: 53 53 💬 |
2656 | Timolol Alcon 0.5% collyre | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
2657 | TJ-68 | - | - | - | - | 1件: 2 2 💬 |
2658 | TJ301 300mg | - | - | - | - | 1件: 97 97 💬 |
2659 | TJ301 600mg | - | - | - | - | 1件: 97 97 💬 |
2660 | TLL-018 | - | - | - | - | 1件: 46 46 💬 |
2661 | TMI-005 | - | - | - | - | 1件: 46 46 💬 |
2662 | TMI-005 (WAY-177005) | - | - | - | - | 1件: 46 46 💬 |
2663 | TMI-005 WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
2664 | TNR-001 | - | - | - | - | 2件: 46 46, 271 💬 |
2665 | TNR-001, TNFR:FC | - | - | - | - | 1件: 271 271 💬 |
2666 | TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | - | - | - | - | 1件: 85 85 💬 |
2667 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2668 | TOBI 300 mg/5 ml Lösung für einen | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2669 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2670 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2671 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2672 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2673 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2674 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2675 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2676 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2677 | TOBI PODHALER*448CPS 28MG+10IN | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2678 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2679 | Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2680 | Tobramycin injection 40mg/1ml | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2681 | Tobramycin solution for inhalation 300 mg | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2682 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2683 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
2684 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2685 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2686 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2687 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2688 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2689 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
2690 | Tofacitinib (CP-690,550) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 96 96 💬 |
2691 | TOFACITINIB CITRATE CP-690550 | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2692 | Tolebrutinib 60mg | - | - | - | - | 1件: 13 13 💬 |
2693 | TOLVAPTAN (OPC-41061) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2694 | TOLVAPTAN 30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2695 | Tolvaptan 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2696 | Tolvaptan 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2697 | Tolvaptan 30mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2698 | TOLVAPTAN 45/15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2699 | TOLVAPTAN 60/30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2700 | Tominersen 60 mg | - | - | - | - | 1件: 8 8 💬 |
2701 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
2702 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
2703 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
2704 | Tozadenant (SYN115) 60 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2705 | TPI-287 6.3 mg/m2 | 1件: TPI-287 TPI-287 | - | - | - | 2件: 5 5, 7 💬 |
2706 | TPN-101, 400 mg/day | - | - | - | - | 2件: 2 2, 127 💬 |
2707 | TRACLEER 62,5 mg comprimidos recubiertos con película | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2708 | TRACLEER 62,5MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2709 | Trametinib (0.5 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
2710 | TransCon CNP 3.9 mg CNP-38/vial | - | - | - | - | 1件: 276 276 💬 |
2711 | TransCon hGH (ACP-011) | - | - | - | - | 1件: 78 78 💬 |
2712 | TransCon hGH (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
2713 | TransCon hGH (ACP-011) - 12.1mg | - | - | - | - | 1件: 78 78 💬 |
2714 | TransCon hGH (ACP-011) - 24.2mg | - | - | - | - | 1件: 78 78 💬 |
2715 | TransCon hGH CT-301 (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
2716 | Transdermal flumazenil (Added 4/2020) | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
2717 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 💬 |
2718 | Treatment Phase Group 4 | - | - | - | - | 1件: 113 113 💬 |
2719 | Treatment with polyethylene glycol (Macrogol 4000) | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 299 299 💬 |
2720 | Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 840 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2721 | Triam 40 mg Lichtenstein | - | - | - | - | 1件: 46 46 💬 |
2722 | Triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2723 | Trientine dihydrochloride 300mg capsules | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2724 | Triomar™ (omega-3 fatty acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
2725 | TRU-015 | 1件: TRU-015 TRU-015 | - | - | - | 3件: 46 46, 49, 222 💬 |
2726 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2727 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2728 | TV-4710 | - | - | - | - | 1件: 49 49 💬 |
2729 | TVP-1012 0.5mg | - | - | - | - | 1件: 6 6 💬 |
2730 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
2731 | TY-0305 | - | - | - | - | 1件: 58 58 💬 |
2732 | TYSABRI 300 mg concentrado para solución para perfusión | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2733 | TYSABRI 300 mg concentrate for solution for infusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2734 | TYSABRI 300 mg solution à diluer pour perfusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2735 | TYSABRI*IV 1FL 300MG 15ML | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2736 | UB-312 | - | - | - | - | 1件: 6 6 💬 |
2737 | UB-312 Injection | - | - | - | - | 2件: 6 6, 17 💬 |
2738 | Ucb 34714 | - | - | - | - | 2件: 149 149, 309 💬 |
2739 | UF-021 | - | - | - | - | 1件: 90 90 💬 |
2740 | UF-021 (isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
2741 | UF-021(isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
2742 | UK 092480 | - | - | - | - | 1件: 86 86 💬 |
2743 | UK-427,857 | - | - | - | - | 1件: 46 46 💬 |
2744 | UK-92,480 | - | - | - | - | 1件: 86 86 💬 |
2745 | UK-92,480-10 | - | - | - | - | 1件: 86 86 💬 |
2746 | ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2747 | Ultomiris 300 mg/30 ml | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 66 66 💬 |
2748 | Ultomiris 300mg/30ml | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2749 | UN-ALPHA-R 0.25µg | - | - | - | - | 1件: 235 235 💬 |
2750 | Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
2751 | Upadacitinib (ABT-494) | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2752 | Upadacitinib 30mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2753 | Upadacitinib 3mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2754 | Updacitinib (ABT-494) | - | - | - | - | 1件: 97 97 💬 |
2755 | Urbason 40 mg | - | - | - | - | 1件: 13 13 💬 |
2756 | URBASON 40 mg comprimidos | - | - | - | - | 1件: 13 13 💬 |
2757 | URSOCHOL 300 | - | - | - | - | 1件: 67 67 💬 |
2758 | Ursodeoxycholic Acid 300mg capsule | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2759 | Ursodeoxycholic Acid 300mg tablet | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2760 | Ustekinumab (approximately 6 mg/kg) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 49 49 💬 |
2761 | Ustekinumab + MTX (Group 3) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 46 46 💬 |
2762 | Ustekinumab 3 mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2763 | Ustekinumab 4.5 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2764 | Ustekinumab 45 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 93 93 💬 |
2765 | Ustekinumab 6 mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2766 | Ustekinumab 90 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 3件: 49 49, 93, 96 💬 |
2767 | Ustekinumab 90 mg (SC) Group 1 | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2768 | Ustekinumab 90 mg (SC) Group 2 | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2769 | Ustekinumab 90 mg SC q12w | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2770 | Ustekinumab 90 mg SC q8w | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2771 | Ustekinumab 90 milligram (mg) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 49 49 💬 |
2772 | Ustekinumab approximately 6 mg/kg (IV) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2773 | Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2774 | Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2775 | UT-15C 0.25 mg | - | - | - | - | 1件: 86 86 💬 |
2776 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 💬 |
2777 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 💬 |
2778 | UX701 (1.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2779 | UX701 (2.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2780 | UX701 (5.0 × 10^12 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2781 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2782 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2783 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2784 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2785 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2786 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2787 | Vamorolone 4% suspension for oral dosing | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
2788 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2789 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2790 | Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana | - | - | - | - | 1件: 19 19 💬 |
2791 | Vedolizumab 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
2792 | Vedolizumab 300 MG Injection [Entyvio] | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
2793 | Vedolizumab 300 mg IV | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
2794 | Vedolizumab IV 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
2795 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 💬 |
2796 | VELCADE*1FL 3,5MG | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
2797 | VELCADE*EV 1FL 3,5MG 1MG/ML | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 💬 |
2798 | Venetoclax Oral Tablet, 400 mg | 1件: Venetoclax Venetoclax | 1件: Venetoclax
Venetoclax
💬 | 1件: BCL2 BCL2 💬 | 43件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Autophagy - animal, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Epstein-Barr virus infection, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, HIF-1 signaling pathway, Hedgehog signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Lipid and atherosclerosis, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prostate cancer, Protein processing in endoplasmic reticulum, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, Toxoplasmosis, Tuberculosis, p53 signaling pathway 💬 | 1件: 28 28 💬 |
2799 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 💬 |
2800 | VEYONDI 650IU powder and solvent for solution for injection | - | - | - | - | 1件: 288 288 💬 |
2801 | VEYVONDI 650IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
2802 | VFEND 40 mg/ml powder for oral suspension | 1件: Voriconazole Voriconazole | 1件: Voriconazole
Voriconazole
💬 | - | - | 1件: 299 299 💬 |
2803 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 💬 |
2804 | VIMOVO 375/20 | - | - | - | - | 1件: 107 107 💬 |
2805 | VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE | - | - | - | - | 1件: 46 46 💬 |
2806 | VIREAD 30 CPR 245 MG | - | - | - | - | 1件: 46 46 💬 |
2807 | Vitamin D3 3000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2808 | Vitamin D3 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2809 | Vitamin D3 4000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2810 | Vitamin D3 6000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2811 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2812 | VOLMAX*30CPR 4MG R.P. | - | - | - | - | 1件: 3 3 💬 |
2813 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2814 | VPRIV 400 Units powder for solution of infusion | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2815 | VRS-317 | - | - | - | - | 1件: 78 78 💬 |
2816 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 💬 |
2817 | VSL#3 | - | - | - | - | 4件: 96 96, 97, 107, 291 💬 |
2818 | VSL#3® | - | - | - | - | 2件: 96 96, 97 💬 |
2819 | VT-001 | - | - | - | - | 1件: 66 66 💬 |
2820 | VWF SD-35-DH | - | - | - | - | 1件: 288 288 💬 |
2821 | VX-371 | - | - | - | - | 1件: 299 299 💬 |
2822 | VX-371 in hypertonic saline | - | - | - | - | 1件: 299 299 💬 |
2823 | VX-371 in saline | - | - | - | - | 1件: 299 299 💬 |
2824 | VX-440 | - | - | - | - | 1件: 299 299 💬 |
2825 | VX-445 | - | - | - | - | 1件: 299 299 💬 |
2826 | VX-445 / TEZ / IVA | - | - | - | - | 1件: 299 299 💬 |
2827 | VX-445 / TEZ / IVA FDC | - | - | - | - | 1件: 299 299 💬 |
2828 | VX-445 /TEZ/IVA | - | - | - | - | 1件: 299 299 💬 |
2829 | VX-445/TEZ/IVA | - | - | - | - | 1件: 299 299 💬 |
2830 | VX-561 (CTP-656) | - | - | - | - | 1件: 299 299 💬 |
2831 | VX-634 | - | - | - | - | 1件: 231 231 💬 |
2832 | VX-659 | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
2833 | VX-659/ TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
2834 | VX-659/TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
2835 | VX-659/Tezacaftor/Ivacaftor | 3件: Ivacaftor Ivacaftor, Tezacaftor, VX-659 | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2836 | VX-661 | - | - | - | - | 1件: 299 299 💬 |
2837 | VX-661 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
2838 | VX-661 Plus Ivacaftor Combination | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2839 | VX-661, VRT-893661 | - | - | - | - | 1件: 299 299 💬 |
2840 | VX-661/Ivacaftor | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2841 | VX-661/ivacaftor (VX-770) 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2842 | VX-661/ivacaftor 100 mg/ 150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2843 | VX-661/ivacaftor 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2844 | VX-661/ivacaftor 100mg/150mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2845 | VX-661/ivacaftor 50 mg/ 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2846 | VX-661/VX-770 | - | - | - | - | 1件: 299 299 💬 |
2847 | VX-661/VX-770 (TEZ/IVA) | - | - | - | - | 1件: 299 299 💬 |
2848 | VX-668 | - | - | - | - | 1件: 231 231 💬 |
2849 | VYNT-0126 | - | - | - | - | 1件: 156 156 💬 |
2850 | White chocolate (0% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
2851 | WILATE 450 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2852 | WILATE 900 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2853 | WILATE® 450 | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2854 | WVE-003 | - | - | - | - | 1件: 8 8 💬 |
2855 | WVE-004 | - | - | - | - | 2件: 2 2, 127 💬 |
2856 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
2857 | XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2858 | XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2859 | XGEVA - 120 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 1.7 ML 4 FLACONCINI | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
2860 | XmAb5871_0.3MG | - | - | - | - | 1件: 46 46 💬 |
2861 | XmAb5871_1.0MG | - | - | - | - | 1件: 46 46 💬 |
2862 | XmAb5871_10.0MG | - | - | - | - | 1件: 46 46 💬 |
2863 | XmAb5871_3.0MG | - | - | - | - | 1件: 46 46 💬 |
2864 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 💬 |
2865 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2866 | Yondelis 0.25 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2867 | Yttrium-90 | 1件: Yttrium Y-90 Yttrium Y-90 | - | - | - | 1件: 28 28 💬 |
2868 | Yttrium-90 radiolabelled anti-CD66 antibody | 1件: Yttrium Y-90 Yttrium Y-90 | - | - | - | 1件: 28 28 💬 |
2869 | Yttrium90 radiolabelled antiCD66 | - | - | - | - | 1件: 28 28 💬 |
2870 | ZD 4522 | - | - | - | - | 1件: 46 46 💬 |
2871 | ZGN-440 | - | - | - | - | 1件: 193 193 💬 |
2872 | ZGN-440 for Injectable Suspension | - | - | - | - | 1件: 193 193 💬 |
2873 | ZGN-440 sterile diluent | - | - | - | - | 1件: 193 193 💬 |
2874 | ZITHOMAX 40 mg/ml ENFANTS | - | - | - | - | 1件: 299 299 💬 |
2875 | Zoenasa-1:4 | - | - | - | - | 1件: 97 97 💬 |
2876 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2877 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product. | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2878 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2879 | ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL | - | - | - | - | 1件: 67 67 💬 |
2880 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2881 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2882 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
2883 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |